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Precipitation with a Compressed Fluid Antisolvent (PCA) and Rapid 
Expansion from Supercritical Solution (RESS) are two processes based on 
supercritical fluids that are capable of producing submicron particles.  Novel 
variations of these basic processes have been examined to produce stable particles 
of various pharmaceutical compounds. 
PCA is an antisolvent precipitation technique where an organic solution of 
drug + polymer in solvent is atomized (sprayed) into supercritical (SC) CO2.  
Upon liquid mixing, the solute materials precipitate to form microparticles.  A 
Vapor-over-Liquid technique has been used to produce larger, uniform particle 
sizes of biodegradable polymers.  By suspending a protein in the solvent phase, 
the protein can be encapsulated/coated by the precipitating polymer. 
viii 
RESS is a process by which a homogeneous solution at supercritical 
conditions is sprayed through an expansion nozzle to atmospheric conditions.  
The resultant change in phase leads to the precipitation of the solute materials.  
The production of extremely small particles (<50 nm) have been predicted but 
rarely demonstrated.  Typically, particle growth occurs to form larger (~1 mm) 
particles.  A novel adaptation was developed, dubbed RESAS (Rapid Expansion 
from Supercritical to Aqueous Solution), wherein the expansion is conducted 
within an aqueous environment.  The aqueous phase can contain surfactant or 
lipid stabilizers to capture and preserve submicron particles of water- insoluble 
drug actives in the form of a suspension. 
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CHAPTER 1 
Introduction 
 
 
 
 
The overall objective of this thesis is to use supercritical fluid-based spray 
methods to produce submicron materials of pharmaceutical compounds.  This 
introductory chapter reviews the properties of supercritical CO2 and two spray 
techniques used to make submicron particles.  Also, an outline of individual 
topics to be discussed in later chapters is presented. 
 
1.1 SUPERCRITICAL CO2 
A material is defined as being supercritical (SC) when the temperature and 
pressure of the system are above the critical point of the fluid.  A supercritical 
fluid has properties between those of a gas and a liquid, and are often referred as 
having gas- like properties at liquid- like densities.  A phase diagram for carbon 
dioxide (CO2) is shown in Figure 1.1.   
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Figure 1.1  Pressure-temperature phase diagram for CO2.  The supercritical 
region is blocked out. 
The physical properties of SC CO2 can be demonstrated by examining the 
density as a function of temperature and pressure at and above the critical point, 
as is shown in Figure 1.2.  At subcritical conditions the density changes only 
slightly until the phase change occurs from gas to liquid.  At supercritical 
conditions, the density dramatically changes over a continuum from low to high 
density.  The most dramatic change in density with pressure is seen just slightly 
above the critical temperature.  As temperature increases, the effect of pressure 
lessens, and extremely high pressures are required to achieve liquid-like densities.  
Similar behavior is observed for other physical properties like viscosity, 
diffusivity, and solubility parameter.1  When using SC CO2 as a solvent, this 
dramatic change in density can be used to “tune” the solvent’s properties.   
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Figure 1.2 Density of CO2 as a function of temperature and pressure. 
 
There are several advantages of CO2-based processes.  CO2 is being used 
to replace many traditional organic solvents and CFC’s since it is essentially 
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nontoxic, inflammable, inexpensive, and environmentally friendly.  It also has 
relatively mild critical conditions, Tc = 31 °C, Pc = 73.8 bar, and so allows 
processing at moderate temperatures to prevent thermal degradation.  Because it is 
a gas at room temperature and atmospheric pressure, there is little or no residual 
solvent left in the materials after processing.  Also, since diffusivities in CO2 tend 
to be higher than for conventional liquids, higher degees of supersaturation can be 
achieved in precipitation techniques relying on solvent mixing.   
 
1.2 PRECIPITATION WITH A COMPRESSED FLUID ANTISOLVENT (PCA) 
Precipitation of a solute from solution to form microparticles by addition 
of a liquid antisolvent is well known.  The liquid antisolvent is chosen such that it 
is miscible with the primary solvent, yet when combined with the solvent, results 
in a lowering of the solubility of the solute.  Thus, the solute precipitates.  The 
morphology of the resultant particles can be controlled by the conditions at which 
the antisolvent addition is carried out, i.e. temperature, rate, drop size, etc.  
Recently, as an alternative to conventional organic liquids, microparticles have 
been formed by precipitation with compressed CO2 in the liquid and supercritical 
fluid states.2-18  The PCA process consists of atomizing a solution into 
compressed liquid or supercritical fluid CO2 as represented in Figure 1.3.  The 
atomization process may be accomplished by spraying at high velocit ies through a 
small nozzle (typically 100 mm) or by sonication14 through a larger nozzle.  The 
organic solvent diffuses rapidly into the bulk CO2 phase, while CO2 diffuses into 
the droplets, thereby precipitating the polymer.  The rate of diffusion in both 
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directions and thus the degree of supersaturation are higher than in the case of 
conventional liquid antisolvents, often resulting in submicron to micron-sized 
particles.  A more in-depth analysis of the mechanism behind particle formation 
in the PCA process is given in Chapter 2. More viscous polymer solutions at 
higher polymer concentrations lead to fibers with micron-sized features.4,8  
Several studies have shown very low concentrations of residual solvent in the 
product materials, especially after a CO2 extraction step upon completion of the 
spray.19-22
Figure 1.3  Schematic diagram of the Precipitation with a Compressed Fluid 
Antisolvent (PCA) process. 
CO2
CO2
solvent 
solution 
CO2 +
solvent 
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Microspheres may be formed for semicrystalline polymers like poly(l-
lactic acid) (l-PLA) without flocculation and agglomeration at 40 °C.19,23,9,11,13,15-16  
Amorphous polymers, on the other hand, such as polystyrene (PS),3,10,12 
poly(methyl methacrylate) (PMMA),10 and poly(dl- lactide-co-glycolide) (PGLA)9 
often flocculate and agglomerate.  The loss of individual particles is a result of 
plasticization of the polymer by CO2, which can be further influenced by residual 
solvent in CO2.  CO2 can depress the Tg  of PMMA by 100 °C below the normal 
value of 105 °C.10,24  Upon exposure of PS to CO2, the temperature at which 
stationary particles agglomerate corresponds closely with the depressed Tg.5  For 
PGLA, agglomeration was present from 0 to 23 °C.9  Severe agglomeration can 
occur when poly(d,l- lactide) microspheres precipitate from toluene solution by 
addition of isopropanol as the phase separating agent.25  However, at temperatures 
between -40 °C and -100 °C the microspheres become sufficiently firm to avoid 
agglomeration.  
1.3 RAPID EXPANSION FROM SUPERCRITICAL SOLUTION (RESS) 
In rapid expansion from supercritical solution (RESS), nucleation and 
crystallization are triggered by reducing the solvent density, or solvent strength, 
through expansion to atmospheric conditions.26-37  Typically, the solution is 
sprayed through a 10-50 mm i.d. nozzle with an aspect ratio (L/D) of 5-100.  A 
schematic diagram representing the RESS process is provided in Figure 1.4.  This 
process has been used successfully to form a variety of microparticles and 
microfibrils from polymers, drugs, and inorganic compounds.  Dissolution rates 
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of poorly-water soluble drugs may be increased by reducing the particle size, to 
increase the surface area, and by inhibiting crystallization to form amorphous 
particles.  Both of these factors may be achieved by RESS according to theoretical 
models of nucleation.  The particle formation steps include nucleation, 
condensation of solute molecules about the nuclei and coagulation of particles in 
the free jet expansion.  The particle morphology has been linked to the location of 
the occurrence of the precipitation conditions (i.e. density), whether in the 
preheater, nozzle entrance, nozzle body, or in the free jet expansion.  Also, it is 
theorized that if coagulation can be minimized, it should be possible to produce 
20-50 nm particles.38-39  The inability to approach the theoretical lower limit is 
likely due to particle growth during collisions in the free jet.38  In cases where a 
cosolvent is used, the particle size tends to be higher, either from a difference in 
supersaturation level or the presence of residual solvent “wetting” the particles.  
Recent work by Charoenchaitrakool et al.40 has produced 2.5 mm particles by 
RESS with enhanced dissolution rates for the poorly water-soluble compound 
ibuprofen, likely due to both the reduction in particle size and crystallinity.40  A 
summary of some recent work conducted with RESS of drug compounds is 
provided in Table 1.1.30,31,37,41-43   
8 
Figure 1.4  Schematic diagram of the Rapid Expansion from Supercritical 
Solution (RESS) process. 
Table 1.1  Summary of solubilities and RESS studies of some pharmaceutical 
compounds in CO2. 
Solute Cosolvent Solubility 
Mass 
fraction (104) 
T 
(°C) 
P 
(bar) 
Mean particle 
Diameter 
(mm) 
Mevinolin 0.09-3.4 55 125-409 0.1-0.3 
Mevinolin 5 % MeOH 10-45 40 103-379 10-50 
Salicylic acid 2.6-21 60 115-325 2-20 
Theophylline 65 225 0.4 
Naproxen 0.4-0.5 60 138-180 1-15 
Progesterone 0.6-52 60 115-240 4-9 
T 
Mach 
Disk 
(Ppre , Tpre) (P0 , T0) 
50 nm > 1mm 
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1.4 THESIS OUTLINE 
Chapter 1 covers work conducted using the Vapor-over-Liquid 
Precipitation with a Compressed fluid Antisolvent (V/L PCA) technique for 
encapsulation of active compounds into polymers.  Lysozyme was encapsulated 
in biodegradable polymer microspheres which were precipitated from an organic 
solution by spraying the solution into carbon dioxide.  The polymer, either poly(l-
lactide) (l-PLA) or poly(dl- lactide-co-glycolide) (PGLA),  in dichloromethane 
solution with suspended lysozyme was sprayed into a CO2 vapor phase through a 
capillary nozzle to form droplets which solidified after falling into a CO2 liquid 
phase.  By delaying precipitation in the vapor phase, the primary particles became 
sufficiently large, from 5 to 70 mm, such that they could encapsulate the 
lysozyme.  At an optimal temperature of -20 °C, the polymer solution mixed 
rapidly with CO2, and the precipitated primary particles were sufficiently hard 
such that agglomeration was reduced markedly compared with higher 
temperatures.  More uniform particles were formed by flowing CO2 at high 
velocity in a coaxial nozzle to mix the droplets at the CO2 vapor- liquid interface.  
This process offers a means to produce encapsulated proteins in poly(dl- lactide-
co-glycolide) microspheres without earlier limitations of massive polymer 
agglomeration and limited protein solubility in organic solvents. 
In Chapter 2, stable suspensions of submicron particles of cyclosporine, a 
water-insoluble drug, produced by Rapid Expansion from Supercritical to 
Aqueous Solution (RESAS) are discussed.  To minimize growth of the 
10 
cyclosporine particles, which would otherwise occur in the free jet expansion, the 
solution was sprayed into an aqueous Tween-80 (Polysorbate-80) solution.  Steric 
stabilization by the surfactant impedes particle growth and agglomeration.  The 
particles were an order of magnitude smaller than those produced by RESS into 
air without the surfactant solution.  Concentrations as high as 38 mg/mL for 400-
700 nm particles were achieved in a 5.0 % (w/w) Tween-80 solution. 
In Chapter 3, RESAS has been used to form stable suspensions of 
submicron particles of cyclosporine A with new surfactant systems based on 
phospholipid vesicles to suspend the particles and minimize growth due to 
particle coagulation during the expansion process.  The ability for the surfactant 
molecules to orient at the surface of the particles and provide steric stabilization 
could be manipulated by changing process variables including temperature and 
suspension concentration.  Suspensions with high payloads (up to 54 mg/mL) 
could be achieved with a mean diameter of 500 nm and particle size distribution 
ranging from 40-920 nm. 
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CHAPTER 2 
Encapsulation of Lysozyme in a Biodegradable Polymer by 
Precipitation with a Vapor-Over-Liquid Antisolvent 
2.1 INTRODUCTION 
Microencapsulation of pharmaceutical compounds in biodegradable 
polymer particles is of great interest for controlled-release in oral, inhalation or 
injection methods of delivery.  Typical methods of microencapsulation include 
emulsion-solvent-extraction, spray-drying, and phase-separation techniques.1-7  
Potential drawbacks associated with these techniques include the use of toxic 
organic solvents for solubility, residual solvent in the microspheres, low 
encapsulation efficiencies due to partitioning of the pharmaceutical compound 
between two immiscible phases, and denaturation.  The biodegradable 
homopolymers poly(l- lactic acid), poly(dl- lactic acid), poly(glycolic acid), and 
copolymers of these have been of particular interest as carrier substances.8-13  
Several supercritical fluid processes have been utilized to form 
microparticles of polymers and pharmaceutical compounds.  To manipulate 
particle morphology, the solvent power of compressed CO2 can be changed by 
adjusting the temperature and pressure.14-15  The critical conditions of CO2 are 
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easily attainable, i.e. Tc = 31 °C and Pc = 73.8 bar. This environmentally benign 
solvent is essentially non-toxic, non-flammable, and inexpensive.  Phase 
separation techniques based upon supercritical fluids include: rapid expansion 
from supercritical solution (RESS),13,16-27 gas antisolvent recrystallization 
(GAS),27-30 and precipitation with a compressed fluid antisolvent (PCA),31-43 also 
known as aerosol solvent extraction system (ASES)44-47 or supercritical 
antisolvent technique (SAS).44  RESS is useful for materials which are soluble in 
CO2.  Unfortunately, CO2, with no dipole moment and a very low polarizability, 
is a very weak solvent and dissolves very few polymers.48-49  RESS of a highly 
soluble polymer, poly(1,1,2,2-tetrahydroperfluorodecylacrylate), from CO2 
produced submicron particles and fibers.24  
Recently, microparticles have been formed by precipitation with 
compressed CO2 in the liquid and supercritical fluid states.
31-47  The PCA process 
consists of atomizing a solution into compressed liquid or supercritical fluid CO2.  
The atomization process may be accomplished by spraying at high velocities 
through a small nozzle (typically 100 mm) or by sonication43 through a larger 
nozzle.  The organic solvent diffuses rapidly into the bulk CO2 phase, while CO2 
diffuses into the droplets, thereby precipitating the polymer.  The rate of diffusion 
in both directions and thus the degree of supersaturation are higher than in the 
case of conventional liquid antisolvents, often resulting in submicron to micron-
sized particles.  More viscous polymer solutions at higher polymer concentrations 
lead to fibers with micron-sized features.33,37  Several studies have shown very 
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low concentrations of residual solvent in the product materials, especially after a 
CO2 extraction step upon completion of the spray.
29,50-52   
Microspheres may be formed for semicrystalline polymers like poly(l-
lactic acid) (l-PLA) without flocculation and agglomeration at 40 °C.29-30,38, 41,43,45-
46  Amorphous polymers, on the other hand, such as polystyrene (PS),32,39,41 
poly(methyl methacrylate) (PMMA),39 and poly(dl- lactide-co-glycolide) 
(PGLA)38 often flocculate and agglomerate.  The loss of individual particles is a 
result of plasticization of the polymer by CO2, which can be further influenced by 
residual solvent in CO2.  CO2 can depress the Tg  of PMMA by 100 °C below the 
normal value of 105 °C.39,53  Upon exposure of PS to CO2, the temperature at 
which stationary particles agglomerate corresponds closely with the depressed 
Tg.34  For PGLA, agglomeration was present from 0 to 23 °C.
38  Severe 
agglomeration can occur when poly(d,l- lactide) microspheres precipitate from 
toluene solution by addition of isopropanol as the phase separating agent.54  
However, at temperatures between -40 °C and -100 °C the microspheres become 
sufficiently firm to avoid agglomeration.  
A novel variation of the PCA process was used to form hollow spheres 
(microballoons) of polystyrene from polystyrene in toluene solutions with 
concentrations above 6 wt.%. 34  In this case the cell was filled only partially with 
liquid CO2, with its equilibrium vapor phase above it.  The solution was atomized 
in the vapor phase and the droplets subsequently fell into the liquid phase where 
they solidified.  By delaying precipitation in the vapor phase hollow microspheres 
were formed.  The microballoons were slightly larger than the diameter of the 
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nozzle, and it is conceivable that they could be used to encapsulate a 
pharmaceutical compound. 
A key challenge in the PCA process is to maintain the biological activity 
of proteins, peptides, and enzymes.35  The dissolution of insulin, lysozyme, and 
trypsin into a typical solvent for PCA, like DMSO, denatures these proteins, 
probably due to a change in conformation.55  Each of these materials remained 
denatured after processing via PCA.  The bioactivity of certain proteins such as 
insulin and lysozyme recover upon redissolution into an aqueous environment, 
suggesting the interactions causing denaturation can be partially reversible.44,56  A 
recent study also suggests that long-term storage of proteins which have been 
denatured by supercritical fluid processing, such as lysozyme, does not severely 
alter the stability and ability to recover bioactivity.57 
The objective of this study was to encapsulate chicken egg-white 
lysozyme into uniform 50-100 mm poly(dl- lactide-co-glycolide) (PGLA) spheres.  
Smaller particles would be too small to encapsulate a significant number of 5-10 
µm protein particles for controlled-release purposes.  Larger particles would be 
undesirable for certain administration methods, for example parenteral 
administration requires particles <100 µm in diameter.58  The first part of this 
study examines the particle morphology for PGLA particles formed by PCA 
without any protein present.  To produce larger primary particles than the 1-5 mm 
particles typically produced by PCA in liquid or supercritical CO2,
31-32,35-36,38-42,44-
45,59 we chose to delay precipitation by spraying into a CO2 vapor phase above a 
CO2 liquid phase.  Another goal was to achieve high enough local concentrations 
18 
of polymer in the droplets striking the CO2 liquid phase to allow significant 
particle growth, while avoiding agglomeration.  To attempt to minimize 
agglomeration caused by plasticization of the polymer by CO2, the temperature 
was varied from 23 to -40 °C.  The effects of nozzle diameter, solution flowrate, 
CO2 flowrate, and solution concentration were also evaluated.  In the second part, 
we address microencapsulation of chicken egg-white lysozyme into the polymer 
particles.  Lysozyme was suspended in dichloromethane, in contrast with earlier 
studies where a protein was dissolved in an organic solvent.27,30,38,43,46  
Suspensions may be formed for a broad range of peptides and proteins, many of 
which are insoluble in organic solvents.  Suspension of a protein in an organic 
solvent typically produces less denaturation than dissolution.  The knowledge 
gained from the study of PGLA particle formation in the first part was utilized to 
encapsulate lysozyme in non-agglomerated particles with diameters in the 50-100 
µm range as desired.  In both parts of this study, separate sections are presented to 
delineate between experiments in static (non-flowing) and flowing CO2.  
2.2 EXPERIMENTAL 
2.2.1 Materials    
Semicrystalline poly(l- lactic acid) (l-PLA) (MEDISORBTM 100L, Stolle-
Dupont Co. Cincinnati, OH) had a Mw of 94,100 and a Mw/Mn of 1.85.  Poly(dl-
lactide-co-glycolide) (PGLA) was purchased from Birmingham Polymers, Inc. 
(Birmingham, AL) and had a Mw of 30,000.  Chicken egg-white lysozyme 
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(Sigma, St. Louis, MO) was spray-dried from aqueous solution to form 1-10 µm 
particles.  Ruthenium tetroxide (Electron Microscopy Sciences, Fort Washington, 
PA), reagent grade dichloromethane and bone dry grade CO2 were used as 
received.  
2.2.2 Apparatus  
The apparatus for precipitation with compressed CO2, shown in Figure 
2.1, is based upon earlier designs.32,39  The solutions were sprayed into a 1.27 
cm. i.d. sapphire tube with a volume of 13 mL.  This tube allowed visual 
observation of skin formation in falling droplets, jet dynamics and polymer 
precipitation.  Visual observations proved invaluable in optimizing the PCA 
process.  A thermostated water bath was utilized for experiments performed above 
0 °C, while a dry ice-ethanol bath was used for subzero temperatures.  For all 
experiments, the CO2 level inside the cell was maintained 1 cm. below the tip of 
the spray nozzle.  The CO2 inlet line (30 feet long, 0.030 inch i.d. by 1/16 inch 
o.d.) was immersed in the bath to equilibrate the CO2 temperature prior to 
introduction into the cell.  
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Figure 2.1. Schematic of the apparatus for precipitation with a vapor-over- liquid 
compressed fluid antisolvent. 
A cylindrical tube (1" o.d. by 11/16" i.d. by 8" long, Autoclave Engineers, 
model CNLX 1608-316) rated up to 689 bar equipped with a piston was used to 
pressurize the polymer solution.  This tube was pressurized with dichloromethane 
by using a computer-controlled syringe pump (ISCO, model 260D). The polymer 
solution was sprayed into the cell via a 100 µm i.d. fused silica capillary tube or a 
0.030" i.d. stainless steel tube.  In all cases, the nozzle length was 6 1/2".  Nozzles 
smaller than 100 µm could not be used because they were plugged by the 
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suspended lysozyme particles.  To insure smoothness, the capillary tips were 
inspected with a microscope.  The lysozyme was suspended in the polymer 
solution by using an ultrasonic bath. 
To collect particles, two small rectangular glass plates (1" by 1/4"), 
slanted at an angle of 60 degrees, were stacked in the bottom of the cell with 
approximately 5 mm between them. These glass plates were partially covered 
with double-sided carbon conductive tape.  Also, a 1/4" diameter 0.5 µm filter 
was placed in the CO2 effluent line at the base of the precipitation cell.   
The solution flow rate was controlled with the automated syringe pump, 
and in most cases the solution was dripped into the cell at 0.1-1.0 mL/min.  The 
solution was injected into a vapor CO2 phase residing above a liquid CO2 phase.  
In some cases, the solution flowrate was increased to ~1.8 mL/min where the 
solution no longer dripped, but instead streamed into the cell.  This stream 
subsequently broke up into smaller droplets upon contacting the CO2 liquid 
surface.  For most cases, the CO2 was not flowing.  In experiments with flowing 
CO2, the CO2 entered the cell either through a port in the top of the cell or 
through an annular region in a coaxial nozzle, described in detail elsewhere.41  
The CO2 flow rate was controlled by a needle valve (Whitey, SS-21RS4) in the 
effluent line and measured by a rotameter (Omega, model FLT-40ST).  To 
prevent freezing due to CO2 expansion, the valve was heated in a water bath to 
greater than 50 °C.  Upon completion of solution injection, the cell was filled with 
liquid CO2 to a pressure of 103 bar.  Liquid CO2 was swept through the cell for 
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10 minutes to remove the dichloromethane and further dry the particles.  After 
drying, the cell depressurized over a 15 minute span.   
2.2.3 Characterization   
Scanning Electron Microscopy (SEM) (Jeol JSM-35C) was used to 
analyze the morphology of the polymer particles.  The glass slides were mounted 
on a SEM stage and coated to an approximate thickness of 200 Angstroms (Pelco 
Model 3 Sputter Coater).       
To detect lysozyme within the particles, two techniques were used.  In the 
first method, the lysozyme was stained by ruthenium tetroxide prior to suspension 
in the polymer solution, and the product was observed with an optical microscope 
(Olympus VANOX-T or Olympus C-35AD-2)) and compared with SEM images 
of the same particles.  Energy dispersive spectroscopy (EDS) was used as the 
second method (Kevex Analyst 8000 Microanalyzer).  Two of the amino acids 
present in lysozyme, cysteine and methionine, contain sulfur, which is not present 
in the polymer, and can be detected by this technique. 
2.3 RESULTS AND DISCUSSION 
2.3.1 Effect of CO2-Dichloromethane Mixtures on Morphology of Polymers 
For the CO2 antisolvent process to be successful, the polymer must be 
highly insoluble in the CO2-organic solvent mixture, and this mixture must not 
cause too much agglomeration of the polymer.  Previously, it was shown that 
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lower molecular weight l-PLA is only slightly soluble in CO2-cosolvent 
mixtures.18  CO2 does not cause l-PLA particles to agglomerate, since they are 
semi-crystalline.38  L-PLA has a melting temperature (Tm) of 173-178 °C and a 
glass transition temperature (Tg) of 60-65 °C (manufacturer's data).  The 
amorphous biodegradable polymer poly(dl- lactide-co-glycolide) (PGLA), 
however, is highly plasticized by CO2.  PGLA has a Tg of 45-50 °C.   
Experiments were performed to determine if CO2 causes PGLA particles 
to agglomerate.  PGLA, as a powder, and in some cases dichloromethane, as a 
liquid, were fed into a high-pressure cell equipped with a sapphire window, which 
has been described previously.60  The cell was sealed, and then liquid CO2 was 
injected slowly into the cell.  From ambient temperature down to 0 °C, PGLA 
powder quickly gels into a viscous mass when in the presence of liquid CO2 for 
concentrations from 0.01 to 1.0 wt %.  At these concentrations, very little polymer 
dissolved, even with up to 5 wt % CH2Cl2 as a potential cosolvent.  The cosolvent 
concentrations were chosen to mimic conditions used in the PCA process.  Upon 
depressurization, the polymer foamed.  At -20 °C, the polymer powder 
occasionally stuck to the wall of the cell, but was also partially suspended 
throughout the cell.  At temperatures below -40 °C the polymer remained as a 
free-flowing non-sticky powder.  Since CO2 acts as a plasticizer, it can lower the 
Tg of the polymer.  The Tg of PGLA containing dissolved CO2 could easily be as 
low as -40 °C, or even lower, based upon other systems mentioned 
previously.34,39,53-54  
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2.3.2 Organic Solvent-CO2 Miscibility and Mixing 
Dichloromethane is highly miscible with CO2 at ambient temperature and 
pressures above 61 bar.  In our investigations, concentrations as high as 73 wt % 
CH2Cl2 were miscible with liquid CO2 at temperatures from 23 °C down to -46 
°C.  The mixing behavior of CH2Cl2 and CO2 was observed inside the sapphire 
cell.  The cell was filled partially with liquid CO2 and equilibrated at the desired 
temperature and pressure.  Pure dichloromethane was then injected into the cell 
through the 100 µm i.d. capillary nozzle.  For conditions where the cell was only 
partially filled with liquid CO2, i.e. vapor and liquid CO2 phases were both 
present, the solvent was injected at flow rates of 0.5 mL/min or slower.  This flow 
rate range prevented the solvent stream from atomizing, and allowed the solvent 
to drip into the liquid phase.  At temperatures ranging from ambient to -20 °C, the 
drops quickly dispersed into the liquid CO2 phase upon contact.  At colder 
temperatures (-30 °C and below) however, the drops were seen to fall about 1 cm 
through the liquid CO2 phase before breaking up.   Operating at temperatures at or 
below -30 °C therefore may be expected to delay precipitation of the polymer 
and/or lead to agglomeration due to insufficient mixing between the drop and 
liquid phases.  While the solvent is still miscible with CO2 at low temperatures, 
the rate of mixing decreases significantly. 
2.3.3 Polymer particles formed in static vapor-over-liquid CO2
As shown in Table 2.1, the concentration of the polymer solution, 
temperature, solution flow rate and CO2 flow rate were manipulated to observe 
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the effect on particle formation.  In this section, the CO2 was static (non-flowing).  
Since both a vapor and a liquid phase are present in each experiment, the initial 
pressure was simply the vapor pressure of CO2 at a given temperature.  At 0 °C 
the pressure was 35 bar, and at -20 °C it was 20 bar.  As the solution was injected, 
the pressure decreased slightly, corresponding to the pressure of the CO2/CH2Cl2 
mixture.  The liquid CO2 level was maintained at 1 cm below the tip of the nozzle 
to allow droplet formation and release from the tip before contact with the liquid 
phase.  With the low flow rate and low shear through the vapor phase, ~200 µm 
drops were formed at a frequency of approximately one per second. 
L-PLA is a semi-crystalline polymer which has been used many times in 
PCA to form microparticles without agglomeration.13,29,38,41,43,45-46  Therefore, we 
first present results for l-PLA to serve as a basis for understanding the more 
challenging experiments with amorphous PGLA.  When a 1.0 % solution of l-
PLA in dichloromethane was dripped into vapor-over- liquid CO2 at 0.5 mL/min 
and 20 °C, the result was microspheres 1-4 µm in diameter, as shown in Figure 
2.2 (top) and Table 2.2.   On the basis of visual observation, it appeared that little 
precipitation occurred before each droplet contacted the liquid phase.  After the 
droplet fell into the liquid CO2 phase, rapid mass transfer led to intense nucleation 
resulting in the small 
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Table 2.1.   Morphology of particles produced by dripping homogeneous 
solutions of amorphous poly(dl- lactide-co-glycolide) and semi-
crystalline poly(l- lactide) in dichloromethane into vapor-over- liquid 
carbon dioxide. 
Poly-
mer 
Csol'n 
(wt%) 
Temp 
(°C) 
Qsol'n 
(mL/min) 
QCO2 
(mL/min) 
Spray 
time 
(min) 
Part. 
size 
(µm) 
Comments 
PGLA 1.0 -20 0.22 0.0 0.35 0.5-5 particles 
5.0 -20 0.22 0.0 0.17 5-70 particles 
5.0 1 0.10 0.0 1.37 10-50 some 500 µm 
agglomerates 
5.0 5 0.10 0.0 0.35 5-15 some 500 µm 
agglomerates 
10.0 -20 4.0 0.0 0.33 --- 1000 µm 
agglomerates 
1.0 -30 0.21 0.0 0.36 --- 1000 µm 
agglomerates 
5.0a -20 0.13 0.0 4.66 --- 1000 µm 
agglomerates 
5.0b -18 0.5 17.5 1.68 3-25 particles 
5.0b,c 0 0.5 35 0.35 10-50 some 500 µm 
agglomerates 
l-PLA 1.0 20 0.5 0.0 0.45 1-4 particles 
5.0c 24 0.5 0.0 0.58 250-
500 
particles 
a 750 µm i.d. nozzle 
bCO2 flow through coaxial nozzle
c0.5 wt. % lysozyme also present 
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Figure 2.2. SEM micrographs of l-PLA microspheres (top) formed by spraying a 
1.0 wt % l-PLA in dichloromethane (CH2Cl2) solution at 0.5 
mL/min  at 20 °C and PGLA microspheres (bottom) formed by 
spraying a 5.0 wt % PGLA in CH2Cl2 solution  at 0.22 mL/min (T= 
-20 °C), both through a 100 µm capillary nozzle into static CO2. 
28 
microspheres.   This result indicates atomization does not play as important a role 
in achieving small particles as suggested previously.41  The particles formed a 
free-flowing powder and could be sprayed for several minutes with no 
agglomeration even as solvent accumulated inside the cell.   
Figure 2.3 is a schematic of a ternary phase diagram consisting of a 
polymer, organic solvent, and compressed CO2.
32  The mass transfer pathways are 
shown only for the lower liquid CO2 phase.  Two of the binary systems are 
completely miscible at most conditions in this study, but the polymer-CO2 binary 
system is only slightly miscible.  The binodal (coexistence) curve separates the 
one-phase and two-phase regions in the ternary system.  Between the binodal and 
spinodal curves is the metastable region.  The system is stable to small 
concentration fluctuations in this region, and phase separation will be by 
nucleation and growth.  Upon crossing the binodal curve for dilute polymer 
solutions, a polymer-rich phase will nucleate and grow within a solvent-rich 
continuous phase.   
For a 5.0 % solution of l-PLA sprayed at similar conditions, we observed 
skin formation on the backlit droplet while it was in the vapor-phase, and the 
resulting particles were 250-500 µm in diameter.  It was easy to observe that the 
liquid droplet became opaque as it fell through the CO2 vapor.  A viscous skin 
appeared to form on the surface of the drop, and the drop did not break up upon 
contact with the liquid CO2.  This observation of skin formation is entirely 
consistent with SEM micrographs, which indicated that the particles were the 
same size as the droplets.  In other experiments, at lower concentrations, where a  
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Figure 2.3. Schematic ternary phase diagram comparing mass transfer pathways 
for precipitation with a compressed fluid antisolvent:  ( ) 
binodal curve, ( ) spinodal curve. 
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skin did not form, a clear transparent droplet fell through the vapor.  With the 
higher polymer concentration, the dissolution of CO2 into the droplet forms a skin 
on the droplet while it is still in the vapor phase.  At this concentration for l-PLA, 
the mass transfer pathway on the phase diagram in Figure 2.3 passes above the 
critical point on the binodal curve (curve B), thus a solvent-rich phase nucleates 
and grows within a polymer-rich phase causing skin formation.  The polymer 
entanglement and viscosity in the skin are sufficient to maintain the integrity of 
the droplet as it solidifies in the liquid CO2, as was observed in a similar system, 
as shown in Figures 4-10 of reference 34.  Here, the final particle size produced in 
each droplet is larger than the nozzle diameter, 100 mm, which was also the case 
for PS in toluene solutions sprayed into vapor over liquid CO2
 34 
In vapor-over-liquid PCA when drops fall through vapor and atomization 
is not present, mass transfer is still fast enough in dilute solutions and is fast 
enough to produce 1-4 mm l-PLA particles, apparently following mass transfer 
pathway A in Figure 2.3.   However, in a previous study with intense atomization 
into liquid CO2 at a high density of 0.96 g/mL, the primary particle sizes were 
even smaller, from 0.1 to 1 mm.41  Not only was atomization more intense 
producing smaller droplets, but the phase boundary was reached more quickly 
from the faster mass transfer.  In addition, the polymer solidified more rapidly 
leading to smaller particles.  Dilute solutions were not studied in the past for V/L 
CO2, as, for example, the concentration was 6 wt. % or higher for PS solutions 
and particles were larger than 100 mm.34   
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For PGLA, the solution concentration was varied from 1.0 to 10.0  wt %.  
To prevent agglomeration, most experiments were performed at -20 °C to raise 
the polymer solution viscosity sufficiently, while maintaining high enough rates 
of CO2-organic solvent mixing (on the basis of the above visual observations of 
mixing).  Also, spray times were generally kept short, <30 sec, to avoid 
accumulating large concentrations of dichloromethane in the static CO2, which 
causes agglomeration.  As the polymer concentration and thus the solution 
viscosity increased, it became necessary to raise the solution flow rate to maintain 
a constant droplet size.  The size was chosen to be slightly larger than the nozzle's 
inner diameter.  At 1.0 wt % and -20 °C, small 0.5-5 µm particles were formed by 
dripping the solution at a flow rate of 0.22 mL/min into CO2.  These non-
agglomerated particles were similar to the l-PLA microspheres shown in Figure 
2.2 (top).  The same experiment conducted at 0 °C and above produced some 
small (0.5-5 µm) primary particles but mostly large (>500 µm) solid 
agglomerates.  Therefore, the polymer particles are significantly more viscous and 
less susceptible to agglomeration at -20 °C.  
As shown in Figure 2.2 (bottom), a 5.0 wt.% solution resulted in 5-70 µm 
microspheres.  At this higher concentration, larger particles may be expected 
because of the higher solution viscosity.  When the large droplet strikes the liquid 
surface, the more viscous solution mixes more slowly with the surrounding liquid 
CO2 and mass transfer rates are slower.  With slower mixing and mass transfer, 
the degree of supersaturation is lower than with less viscous solutions (lower 
concentrations), resulting in fewer nuclei per weight of polymer.  Because most of  
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the nuclei tend to be formed in a small volume where the droplet falls, 
coalescence of primary particles is more prevalent than for the experiments with 
lower polymer concentrations, where faster mixing occurs.  With the reduction in 
nucleation rate and higher polymer concentrations (which produces faster 
agglomeration), especially in a local volume where the drop falls, larger particles 
are formed.   
Unlike previous studies for polystyrene with the same vapor-over-liquid 
technique, these particles are much smaller than the initial droplet size, which was 
~ 200 µm.  For 6 wt % polystyrene (200,000 MW) in toluene solutions, 300 µm 
diameter microballoons are formed with a 151 µm nozzle.34  A skin, about 20 µm 
thick, forms on the droplet while still in the vapor phase which then hardens upon 
contact with the liquid phase.  The polymer entanglement and viscosity in the skin 
are sufficient to maintain the integrity of the droplet as it solidifies in the liquid 
CO2.  The PGLA in this study has a much lower molecular weight (~30,000) and 
the solutions are much less viscous.  Also, the miscible region in the phase 
diagram in Figure 2.3 is larger for PGLA-dichloromethane-CO2 than for PS-
toluene-CO2 because of the lower molecular weight for PGLA versus PS and the 
lower solubility parameter of dichloromethane versus toluene.  Consequently, it 
will take longer for PGLA to precipitate on the mass transfer pathway on the 
phase diagram (Figure 2.3), delaying skin formation.34  Without any visual 
indication of skin formation in the vapor phase, smaller particles are produced, as 
the droplet breaks up on contact with the liquid phase.  
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At dilute concentrations, PGLA does not appear to form a skin when 
contacting CO2 vapor, and the particles do not form unt il the large droplet has 
begun to disperse in the liquid CO2 phase.  When the solution concentration is 
increased to 10 wt. %, the solution becomes extremely viscous and individual 
particles are not formed, only large agglomerates, >1000 µm.  Here, a thin skin is 
visible on the droplets while they are being formed in the vapor phase, although 
the microscopic structure of the skin could not observed with the naked eye.  The 
formation of a skin was confirmed by examination of the samples with SEM (not 
shown).  Skin formation is favored by the higher solution viscosity and high 
concentration, which may shift the mass transfer pathway above the critical point 
(see Figure 2.3).  This shift would cause solvent-rich domains to nucleate and 
grow within a polymer-rich domain.34,37  The thin skin is weak, since it contains a 
high concentration of dissolved CO2, and it was easy to observe visually that the 
skin immediately ruptures upon hitting the CO2 liquid surface.  The ruptured skin 
appeared as large agglomerates or films when examined by SEM (not shown).  
The mixing and diffusion of solvent away from the droplet are very slow due to 
the high polymer concentration and viscosity, resulting in severe agglomeration.   
When a polymer solution is sprayed at 1.0 mL/min into flowing liquid 
CO2 (without a CO2 vapor phase) we found that fibers are produced for PGLA 
concentrations above 1.0 wt.%.  Fibers are formed from the jet due to the rapid 
nucleation, high solution concentration, high solution viscosity (to prevent 
atomization) and skin formation.33  In experiments with vapor-over-liquid CO2, 
the large droplets are formed instead of a jet (at the same flow rate) due to much 
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higher interfacial tension because of the low CO2 density .  The precipitation in 
the droplets is slower than in the case of a jet due to the larger dimensions of the 
solution phase and lower miscibility between the phases for CO2 vapor compared 
with CO2 liquid.  As a result, fibers are not formed.  
The opposing effects of temperature on particle growth, coalescence, and 
mixing between the phases must be properly balanced to produce large non-
agglomerated particles.  As temperature is decreased the polymer solution 
becomes more viscous, which will cause coalescence to be less prevalent.  Some 
coalescence, however, will aid the formation of the desired 50-100 mm particles 
rather than the typical 1-5 mm particles.  As mentioned earlier, decreasing the 
temperature below -20 °C slows the mixing between the solvent and CO2 phases.  
When a 1.0 % solution of PGLA in dichloromethane was dripped into liquid CO2 
at -30 °C, no distinct particles were formed, only large agglomerates, due to the 
slow mixing.   When the solution droplets fell, they initially formed a pool at the 
liquid surface, and then penetrated the surface.  The polymer began to precipitate 
at the interface, forming a film, and occasionally droplets fell through the film and 
agglomerated.  Previously, we showed that PGLA particles exposed to CO2 do 
not tend to agglomerate at -40 °C, indicating hard particles or even a glassy state.  
Unfortunately, the rate of mixing between the organic solvent and the liquid CO2 
is too slow at -30 °C and -40 °C to disperse the polymer.   
At temperatures higher than 0 °C, agglomeration also occurred readily.  As 
seen in Figure 2.4 (top), a 5.0 wt.% solution dripped into liquid CO2 at 1 °C 
yielded some distinct particles in the 10-50 µm range, but the polymer was 
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partially agglomerated.  This occurred for every experiment at 0 °C or above since 
the polymer is excessively swollen by CO2 and the viscosity is too low at these 
temperatures.   
A 0.030" i.d. (~750 µm) stainless steel nozzle was used to form larger 
initial droplets in order to attempt to produce the desired particle size.  For PGLA 
concentrations of 1.0 and 5.0 wt. %, and temperatures from -20 °C to 4 °C, the 
particles were always severely agglomerated with few, if any, distinct particles.  
The large drops formed more slowly, providing more time for precipitation to 
occur which allowed a thin skin to form on the large droplets while in the vapor 
phase.  On the basis of visual observation, this skin was weak and ruptured upon 
impact with the liquid CO2 surface.  The larger droplet size produced a larger 
local concentration of polymer and solvent, which caused severe agglomeration of 
the polymer.   
2.3.4 Polymer particles formed in flowing vapor-over-liquid CO2
Experiments were performed with flowing CO2 to minimize CH2Cl2 
accumulation.  CO2 was passed through the annular region of a coaxial nozzle, 
described previously,41 at high velocity (69-138 cm/s) to agitate the surface of the 
liquid phase to enhance mixing.  Figure 2.4 (middle and bottom) shows PGLA 
particles formed by spraying a 5.0 wt % solution at 0.5 mL/min into the cell 
through a 100 µm capillary nozzle with CO2 flowing at 17.5 mL/min and at -20 
°C.  Vigorous mixing was observed at the interface, such that particles nucleated 
and grew throughout the liquid phase rather than in a local region where the 
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droplets fell.  The resulting spherical particles ranged in size from 3-25 µm in 
diameter with no agglomeration even after almost 2 minutes of spraying.  The 
difference in results was dramatic compared to the case for static CO2.  The 
particles were suspended throughout the cell, but plugging of the frit in the 
effluent line at the bottom of the cell limited spray times.  This problem could be 
reduced in the future with a larger filter.  The increased mixing causes a higher 
degree of supersaturation, more nucleation, faster solvent removal and quenching, 
and less time for growth.  The result was far less coalescence and agglomeration 
when compared to the case with static CO2.  Experiments were also run at higher 
temperatures to determine if the increased mixing was enough to prevent 
agglomeration.  For all cases where the temperature was 0 °C or higher, some 10-
50 µm particles were formed, but mostly large (>500 µm) agglomerates were 
formed.  The particles were not sufficiently hard at the higher temperatures to 
prevent coalescence. 
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Figure 2.4. SEM micrographs of PGLA microspheres formed 
by spraying a 5.0 wt % PGLA in CH2Cl2 solution at 0.1 mL/min 
(T=1 °C) into static CO2 (top) and at 0.5 mL/min into CO2 flowing 
at 17.5 mL/min at -20 °C (middle and bottom) through a 100 µm 
capillary. 
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2.3.5 Encapsulation of lysozyme into PGLA with static CO2 
In control experiments, lysozyme suspensions in CH2Cl2 were sprayed 
into CO2 through a 100 µm capillary nozzle at temperatures from 23 to 0 °C.  The 
lysozyme suspensions were formed with an ultrasonic bath and were stable for 
hours.  The suspension flowed smoothly through the capillary and the particle size 
(1-10 µm) and morphology of the product were identical to those of the original 
lysozyme, which is shown in Figure 2.5.  The original spray-dried lysozyme 
particles and those removed after spraying into CO2 were "bowl-shaped" when 
examined by SEM.  Since the polymer particles discussed previously were 
spheres, it is easy to distinguish between polymer and protein particles.  
Figure 2.5. SEM micrograph of spray-dried lysozyme particles. 
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Table 2.2 summarizes results of encapsulating lysozyme into PGLA.  
Again, the temperature was chosen as -20 °C to strike a balance between mixing 
favored at high temperatures and formation of hard, non-sticky particles in CO2 
which is favored at low temperatures.  An initial loading of 10:1 by weight of 
polymer to protein was maintained in each case.  Figure 2.6 (top) shows the result 
of spraying a 1.0 wt. % solution of PGLA with lysozyme into static CO2.  The 
primary particle size was 0.5 - 5 µm in diameter with very little encapsulation of 
the similarly-sized protein particles.  The solution was too dilute for polymer 
particles to encapsulate a significant fraction of the protein particles.  This result 
was anticipated, since it was shown above that small 0.5-5 µm PGLA particles are 
formed by precipitation from a 1.0 wt. % solution, which are too small to coat the 
lysozyme particles. 
For a PGLA concentration of 5.0 wt. %, the particles are in the 5-60 µm 
diameter range, and the encapsulation efficiency is substantial, as demonstrated in 
Figure 2.6 (bottom).  Here, the magnification is high enough to examine a single 
particle.  The craters or holes in the polymer particle represent protein particles 
for the following reasons.  In identical experiments without protein, the craters 
were never present.  Also, the size of the craters matches those of the pure protein 
particles.  Further evidence that the craters represent protein particles is given 
below in the subsection on experiments with flowing CO2.  
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Table 2.2.   Morphology of particles produced by dripping homogeneous 
solutions of amorphous poly(dl- lactide-co-glycolide) and semi-
crystalline poly(l- lactide) in dichloromethane containing suspended 
lysozyme into vapor-over- liquid carbon dioxide. 
Poly-
mer 
Csol'n 
(wt%) 
Temp 
(°C) 
Qsol'n  
(mL/
min) 
QCO2 
(mL/
min) 
Spray 
time 
(min) 
Particle 
size 
(µm) 
Encapsulation 
PGLA 
/ lyso. 
1.0 /0.1a -23 0.1 0.0 0.48 0.5-5 no 
5.0 / 0.5 -20 0.1 0.0 1.28 10-60 yes 
5.0 / 0.5 -20 0.5 0.0 0.63 10-50 yes 
5.0 / 0.5 -20 1.5 0.0 0.28 5-50 yes 
5.0 /0.5b -20 1.8 0.0 0.18 5-60 yes 
5.0 /0.5c -20 0.5 25 0.42 5-30 yes 
5.0 /0.5d -21 0.5 35 0.82 >1000e no 
l-PLA 
/ lyso. 
1.0 / 0.1 20 0.1 0.0 3.23 0.5-2.5 no 
5.0 / 0.5 24 0.5 0.0 0.58 250-500 yes 
a1.0 wt. % PGLA, 0.1 wt. % lysozyme 
bonset of streaming due to high Qsol'n 
cCO2 flow through coaxial nozzle
dCO2 flow enters from top of cell
eagglomerates 
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Figure 2.6. SEM micrographs of PGLA microspheres formed by spraying a 
1.0/0.1 wt % (top) and a 5.0/0.5 wt % (bottom) PGLA/lysozyme 
suspension at 0.1 mL/min in CH2Cl2 through a 100 µm capillary 
nozzle into static CO2 at -20 °C. 
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At lower magnifications, the particles looked similar to those shown in 
Figure 2.2 (bottom).  Apparently, the presence of the small, encapsulated protein 
particles does not have a significant influence on the polymer particle size.  The 
polymer particles are much larger than in the case of a 1.0 wt.% solution, and are 
large enough to encapsulate multiple protein particles.  Also, since the solution is 
more concentrated, the probability of a polymer particle nucleating and growing 
next to a lysozyme particle is enhanced.  Also, the protein has the potential to act 
as a nucleating agent for the polymer.  The large droplets formed in the CO2 
vapor phase lead to relatively slow mixing when the droplets strike the liquid CO2 
phase.  The high local concentrations of the sticky CO2-swollen polymer and 
protein lead to a large amount of growth.   
A desirable feature of this spray geometry is that a polymer-rich phase 
nucleates in the presence of the protein in the confined space of the droplets, 
which occupy a small volume fraction compared to the total volume.  Such 
nucleation may be expected to produce higher encapsulation efficiencies than if 
the polymer nucleated throughout the total cell volume.  This advantage of 
compartmentalization of polymer and protein is not present in the GAS process 
cited above where CO2 is added to a liquid solution.  A disadvantage of the V/L 
PCA process is that the primary mass transfer takes place at the vapor-liquid 
surface rather than throughout the entire volume, which can lower the production 
rate.     
Varying the size of the droplets leaving the nozzle could potentially lead 
to a change in size of the polymer particles.  As the flow rate of the polymer 
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solution increased, it was observed that the droplet size decreased.  However, no 
significant change in particle morphology occurred when the solution flow rate 
was increased from 0.1 to 1.5 mL/min for a 5.0 wt.% solution at -20 °C.  In each 
case, the particles appeared as those shown in Figure 2.6 (bottom).  A 
complication of extremely slow flow rates is plugging of the nozzle, which 
occurred very often at 0.1 mL/min, but infrequently at 0.5 mL/min or higher.  
This plugging is likely a result of precipitation inside the nozzle, caused by CO2 
diffusing upwards into the nozzle, and/or entrapment of the solid protein particles.   
The degree of agglomeration of the polymer product is dependent upon 
the solution flow rate and spray time.  When conducting the spray, at a certain 
time large particles could easily be seen with the naked eye.  When analyzed by 
SEM, these large particles were agglomerates and not simply large flocculates of 
small primary particles.  At a solution flow rate of only 0.1 mL/min, the 
experiment could be run for 1 minute before agglomeration began to occur.  For 
higher flow rates, the observed time where large particles appeared decreased 
accordingly to 40 and 20 seconds at flow rates of 0.5 and 1.5 mL/min, 
respectively.   This agglomeration could potentially be avoided by either flowing 
CO2 continuously through the cell as described in the next section or by spraying 
into a larger volume cell.  At 1.8 mL/min, streaming of the solution begins to 
occur rather than dripping.  Here, the range of particle sizes did not change, but 
there was a higher percentage of large particles compared to the previous cases at 
lower flow rates.  Due to the large amount of solution flowing into the cell, 
agglomeration began to occur after only 10 seconds.   
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2.3.6 Encapsulation of lysozyme into PGLA with flowing CO2 
Figure 2.7 compares an optical micrograph and a SEM micrograph  of 
polymer particles with protein particles visible on the surface.  These particles 
were formed by spraying a 5.0 wt.% PGLA solution with suspended lysozyme at 
0.5 mL/min along with CO2 flowing in the annulus at a velocity of 138 cm/s.  The 
SEM image (top) shows particles with craters or holes in their surfaces, which 
may be identified as the "bowl" shaped spray-dried lysozyme particles.  The 
micrograph taken with the optical microscope (bottom) shows the same polymer 
particle with encapsulated stained protein particles.  The stained protein directly 
corresponds to the craters observed in the SEM micrograph.  This correspondence 
between optical and SEM photomicrographs was always observed where we 
compared images of particles formed by the vapor/liquid PCA process. Figure 2.8 
(top) shows 40-70 µm particles with encapsulated lysozyme formed at the same 
conditions as Figure 2.7, except at a higher CO2 flow rate.  By varying the focal 
plane throughout the depth of the particle (not shown), we observed in the optical 
microscope that the protein particles were encapsulated throughout the PGLA 
particles and were not just on the surface.  While there did not appear to be any 
protein particles that were not encapsulated, polymer particles without 
encapsulated protein were present.  
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Figure 2.7. SEM micrograph (top) and optical micrograph (bottom) of PGLA 
microspheres formed by spraying a 5.0/0.5 wt % suspension of 
PGLA/lysozyme in CH2Cl2 at 0.5 mL/min through a 100 µm 
capillary nozzle into CO2 flowing at 15 mL/min at -20 °C. 
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Flowing CO2 at high velocity during the spray delayed the time at which 
large particles were observed visually in the tube.  This time corresponded to the 
time where agglomeration was observed in the SEM micrographs.  Flowing CO2 
through the annular region surrounding the nozzle at high velocity caused a large 
amount of mixing at the vapor/liquid interface and suspended the precipitated 
particles throughout the cell, yielding spherical, non-agglomerated particles.  
Spraying a 5.0%/0.5% PGLA/lysozyme solution at 0.5 mL/min into the cell at -20 
°C with CO2 flowing at 25 mL/min yielded spherical particles 5-30 µm in 
diameter, with encapsulation of the protein as seen in Figure 2.8 (bottom).  These 
particles are more uniform in size and shape than those formed in static CO2, and 
appear like those in Figure 2.4 (middle).  The particle sizes are more uniform in 
this case due to better mixing at the vapor-liquid interface.   
In another type of experiment, CO2 was introduced into the cell through a 
large opening located in the top of the cell 1 cm above the tip of the nozzle.  Here, 
the CO2 velocity was relatively low and turbulence from the CO2 did not have 
much effect on the solution stream or on the CO2 vapor/liquid interface.  The 
purpose of flowing CO2 was to reduce the accumulation of solvent in the cell.  
Spraying a 5.0%/0.5% PGLA/lysozyme solution at 0.5 mL/min into CO2 flowing 
at 35 mL/min at -21 °C yielded little change in particles size and failed to delay 
the onset of agglomeration, compared to the case with static CO2.  The same was 
true for higher CO2 flow rates up to 52 mL/min.  With this cell configuration, the 
CO2 stream does not cause significant turbulence or mixing inside the cell.  Since 
agglomeration occurred at the same time as in static CO2 experiments, most of the  
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Figure 2.8. SEM micrograph (top) and optical micrograph (bottom) of PGLA 
microspheres formed by spraying at 0.5 mL/min a 5.0/0.5 wt % 
PGLA/lysozyme suspension in CH2Cl2 through a 100 µm capillary 
nozzle into CO2 flowing at 25 mL/min at -20 °C. 
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agglomeration occurs immediately after precipitation and not after solvent 
buildup in the cell.  In this case the particles were concentrated at the liquid-vapor 
interface and were not suspended throughout the liquid phase.   
Elemental analysis via Energy Dispersive Spectroscopy (EDS) was also 
used to confirm the presence of lysozyme in the polymer particles.  Lysozyme has 
2 amino acid constituents containing sulfur, cysteine and methionine, which can 
be detected via EDS.  Chicken egg white lysozyme is reported to contain 8 
cysteine molecules and 2 methionine molecules per protein chain.61-62  Both of 
these amino acids have one sulfur atom per molecule, resulting in 10 per 
lysozyme molecule.  EDS scans of the pure protein (top) and particles with 
encapsulated protein (bottom) are shown in Figure 2.9.  The analysis of the pure 
lysozyme shows peaks corresponding to the presence of phosphorus, chlorine, and 
potassium impurities as well as the sulfur.  Analysis of the peaks is only 
qualitative, unfortunately, due to multiple scattering of the x-rays.  Particles 
formed by spraying a 5.0% PGLA solution with suspended lysozyme were 
analyzed as shown in Figure 2.9 (bottom).  The lower curve represents a polymer 
particle with no protein present, while the upper curve corresponds to a single 
polymer particle with entrapped lysozyme.  The particles were collected on a 
section of a glass slide, thus explaining the presence of the silicon impurity peak. 
The presence of the other peaks, excluding silicon, indicates that lysozyme was 
encapsulated within the polymer particle examined.   
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Figure 2.9  EDS scans of spray-dried lysozyme (top) and PGLA microspheres 
(bottom) formed by spraying a 5.0/0.5 wt % suspension of 
PGLA/lysozyme at 0.5 mL/min in CH2Cl2 through a 100 mm 
capillary nozzle into CO2 flowing at 15 mL/min at –20 °C. 
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2.3.7 Encapsulation of lysozyme into l-PLA 
When polymer particles are similar in size to the protein particles, little or 
no encapsulation is expected to occur.  Figure 2.10 (top) shows particles formed 
by spraying a 1.0% l-PLA solution with suspended lysozyme at 0.1 mL/min and 
20 °C.  As shown, the 1-4 µm polymer particles do not tend to encapsulate the 
lysozyme particles.  Therefore, the polymer precipitation occurs without requiring 
the protein as a nucleation site.  Solutions with higher polymer concentrations will 
tend to form larger particles as evidenced earlier for PGLA.  Spraying a 5.0% l-
PLA solution at 0.5 mL/min and 24 °C resulted in particles 250-500 µm in 
diameter, Figure 2.10 (bottom).  This polymer precipitates very rapidly and a 
polymer skin quickly forms on the droplet while still in the CO2 vapor phase.  
The high solution viscosity caused the drop size to be larger than the nozzle inner 
diameter, and the resultant particle diameter was the same as the initial drop size.  
In this case the large polymer particles appeared to encapsulate all of the protein 
particles, as no individual protein particles were found on the sample slides.   
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Figure 2.10. SEM micrographs of l-PLA microspheres formed by spraying a 
1.0/0.1 wt % l-PLA/lysozyme suspension at 0.1 mL/min at 20 °C 
(top) and a 5.0/0.5 wt  % l-PLA/lysozyme suspension at 0.5 mL/min 
at 24 °C (bottom) through a 100 µm capillary nozzle into static CO2.   
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2.4 CONCLUSIONS  
Several major challenges for the PCA process were overcome in order to 
encapsulate a protein into PGLA.  The PGLA particles were large enough to 
encapsulate the protein and did not agglomerate.  In contrast, the primary particles 
(0.5 to 5 mm) were too small for encapsulation when the solution was sprayed into 
liquid or supercritical CO2; furthermore, the particles were highly agglomerated.   
By delaying precipitation in a vapor CO2 phase over a liquid CO2 phase, much 
larger primary particles were formed, from 5 to 70 mm.  At an optimal 
temperature of -20°C, the polymer solution mixed rapidly with CO2, and 
agglomeration of primary particles was minimal due to harder particles than at 
higher temperatures. 
The amorphous polymer PGLA is highly plasticized by CO2.  Dissolution 
of CO2 into PGLA depresses the Tg from the normal value of 45 °C to 
approximately -40 °C at 276 bar, based upon observation of particle 
agglomeration.  Below -40°C, the polymer remains as a non-sticky free-flowing 
powder in the presence of CO2 at 276 bar.  Below -30°C, the rate of mixing 
between CH2Cl2 and liquid CO2 decreases appreciably.  At an optimal 
temperature of -20 °C, the highly viscous PGLA microspheres do not 
agglomerate, yet the temperature is high enough to achieve adequate mixing 
between liquid CO2 and the organic solution.  An additional benefit of operating 
at colder temperatures is the relatively low pressure.  At -20°C, the saturation 
pressure of CO2 is 19.7 bar, compared to 61.4 bar at 23 °C. 
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The vapor-over-liquid PCA process forms microspheres in the 5-70 µm 
range when a 5.0 % solution of PGLA in dichloromethane is sprayed at 0.22 
mL/min through a 100 µm diameter nozzle into static CO2 at -20 °C.  
Experimental temperatures of 0 °C or above, or below -30°C yielded only large 
(>1000 µm) agglomerates.  At high temperatures the particles are too sticky due 
to dissolved CO2, and at low temperatures, the organic solution and CO2 mix too 
slowly.  Lower concentrations yielded smaller primary particles whereas highly 
viscous concentrated solutions above 10.0 wt. % led to skin formation in the 
vapor phase and subsequent agglomeration in the liquid CO2 phase.  The thin skin 
is weak due to low molecular weight and dissolved CO2, and hence rupturing 
occurs upon impact at the liquid interface leading to agglomeration.  Particle sizes 
did not change appreciably with solution flow rate in the "dripping" regime.  At 
the onset of streaming flow, there was a higher percentage of large particles, 
while the particle size range remained the same.  The most spherical and uniform 
particles ranging in size from 3-25 µm in diameter were produced by flowing 
CO2 at high velocity through an annular region in a coaxial nozzle to provide 
mixing at the interface.   
Encapsulation of 1-10 µm lysozyme particles proved successful for the 5-
70 µm PGLA microspheres for a 1:10 ratio by weight of protein to polymer and a 
5 wt % polymer solution.  The presence of lysozyme in the particles was 
demonstrated by SEM analysis, optical microscopy, and EDS.  A high 
encapsulation efficiency for this process is favored by the fact that the protein and 
polymer precipitate together in small droplets.  The use of protein suspensions 
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extends the applicability of the PCA process substantially, since many proteins 
are insoluble in organic solvents and are less likely to be denatured when 
suspended. 
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CHAPTER 3 
Rapid Expansion from Supercritical to Aqueous Solution to 
Produce Suspensions of Water-Insoluble Drugs 
3.1 INTRODUCTION  
A large number of drugs are insoluble or poorly soluble in water.  Hence, 
the clinical utility of the available pharmaceutical dosage forms can be limited by 
this insolubility.  An alternative approach for the formulation of water- insoluble 
biologically active compounds is surface-stabilized micron- or submicron-size 
particulate preparations.  The pharmacokinetic properties of both oral and 
injectable formulations are dependent on the particle size. Small particles are 
often needed in order to maximize surface area, to improve bioavailability, and 
for dissolution requirements.  Pace et al. have reviewed the usefulness of 
microparticulate preparations of water- insoluble or poorly soluble injectable 
drugs.1  Current techniques for micronizing solids include spray drying2-3, 
emulsion-solvent-extraction4-6, and processes based on high shear, cavitation, 
attrition, and/or impaction (microfluidization, high pressure homogenization, ball 
milling, media milling, air jet milling).7-11  There can be several drawbacks 
associated with these techniques, including broad particle size distributions and 
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denatured products caused by exposure to high temperatures (observed in jet 
milling), lengthy periods for residual solvent extraction (in the spray drying 
process), and separation of processing agents that may be undesirable in the final 
formulation (in ball milling or media milling processes). 
The overall objective of this work is to use an alternative method for 
particle size reduction based on rapid expansion from supercritical fluids, 
especially CO2.  CO2 is an environmentally benign solvent that is non-flammable, 
inexpensive, and essentially non-toxic. It has relatively mild critical conditions, Tc 
= 31 °C and Pc = 73.8 bar, allowing processing of thermally labile materials in a 
medium which has gas- like transport properties at liquid- like densities. CO2 has 
no dipole moment and a very low polarizability per volume.  Therefore, only 
certain water- insoluble pharmaceutical compounds are soluble, particularly those 
with low melting points.  A recent review12 summarizes the solubility of many 
pharmaceutical compounds of interest in supercritical CO2.  In some cases, the 
solubility was enhanced by the addition of a cosolvent, such as an alcohol.   
In rapid expansion from supercritical solution (RESS), nucleation and 
crystallization are triggered by reducing the solvent density, or solvent strength, 
through expansion to atmospheric conditions.12-23  Typically, the solution is 
sprayed through a 10-50 mm i.d. nozzle with an aspect ratio (L/D) of 5-100.  This 
process has been used successfully to form a variety of microparticles and 
microfibrils from polymers, drugs, and inorganic compounds.  An example of a 
highly soluble polymer, which has been used in RESS to form submicron 
particles and fibers, is poly(1,1,2,2-tetrahydroperfluorodecylacrylate).15  Most 
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particle sizes reported have been between 5-100 mm.  From theoretical 
calculations, it should be possible to form particles as small as 20-50 nm.24  The 
inability to approach the theoretical lower limit is likely due to particle growth 
during collisions in the free jet.24  Nanoparticles of beta-carotene (300 nm) were 
formed by expansion within a valve of an ethylene solution, which then flowed 
into a 10% (w/w) viscous gelatin solution in order to inhibit post-expansion 
particle agglomeration.19  Phospholipids and other surface modifiers in aqueous 
solution have been utilized to stabilize aqueous suspensions produced by RESAS 
of CO2 solutions.25  In both of these studies, the suspensions were much less 
concentrated than those in the present study. 
The goal of this work was to produce aqueous suspensions of water-
insoluble drugs by RESS with an average particle size of less than 1 mm at 
substantial drug concentrations, e.g. above 20 mg/mL.  High concentrations of 
water-insoluble drugs are of great interest for parenteral administration.  The 
supercritical solutions were sprayed directly into an aqueous surfactant solution in 
order to stabilize small particles by minimizing flocculation and agglomeration 
resulting from particle collisions. The surfactant was chosen to be active at the 
drug-water interface, but need not be active at the CO2-drug interface. Tween-80, 
a non-ionic surfactant (polyoxyethylene sorbitan monooleate C64H124O26), was 
chosen to sterically stabilize the drug particles. It is approved by the US Food and 
Drug Administration for use as an excipient in either oral or parenteral delivery 
formulations.  If the surfactant can rapidly adsorb to the surface of the growing 
particles in the free jet, it may stabilize submicron particles.  The solubilities of 
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several drugs in CO2 were measured to determine if they were large enough for 
RESAS.  Cyclosporine, a water- insoluble immunosuppressant for organ 
transplantation, was used as a model drug for this study, since it is soluble in CO2 
and is of interest in parenteral administration. To evaluate the effectiveness of the 
process, the concentration of drug in the suspension was measured by high 
performance liquid chromatography (HPLC) and particle sizes were measured by 
dynamic light scattering (DLS). 
 
3.2 EXPERIMENTAL 
3.2.1 Materials and Analytical Methods  
Cyclosporine A was obtained from North China Pharmaceutical 
Corporation.  Flurbiprofen was obtained from Sigma and Piroxicam from Cipla.  
These drugs were used without further purification.  Instrument Grade CO2 was 
used for all experiments.  Tween-80 was purchased from Fisher Scientific.  The 
aqueous solutions consisted of 1.0 and 5.0 % (w/w) Tween-80, and these 
concentrations are higher than the critical micelle concentration.  Water was 
purified to Type 1 reagent grade by passing it through a Barnstead (NANOpure 
II) filtration system.   
Separation and quantification of drug concentrations in the aqueous 
solutions were achieved by high performance liquid chromotography (HPLC) 
with a 250 mm long C-18 column (SGE ODS - 5mm).  Five mL of methanol was 
added to 0.5 mL of each sample, 9.6 mL of which was injected into the system.  
Methanol was used as the mobile phase, and the detection wavelength was 210 
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nm.  The solubility of drug in aqueous Tween-80 solutions was determined from 
the saturated solutions at 10 °C and 22 °C.  An excess amount of drug was added 
to 1-20 % (w/w) aqueous Tween-80 solutions, stirred for 1 hr., and then allowed 
to equilibrate for 1 week at 10 °C and 22 °C.  The dissolved amount of drug was 
determined from a filtrate of these saturated solutions by the above-mentioned 
HPLC method. 
Dynamic light scattering (DLS) measurements were conducted with a 
Brookhaven Zetaplus (Brookhaven Instruments Corporation, New York) to 
determine particle sizes in terms of number-weighted, mass-weighted, and 
intensity-weighted size distributions.  The time between the formation of the drug 
suspensions and analysis was 1-3 days. 
3.2.2 Phase Behavior and Rapid Expansion from Supercritical Solution 
The drug phase behavior in CO2 was determined with a high-pressure 
variable-volume cell that is discussed in detail elsewhere.26  The cell was 
equipped with a sapphire window, allowing visual observation of the phase 
behavior.  A predetermined amount of drug was loaded into the front of the cell, 
and then the cell was sealed.  CO2 was metered into the front of the cell and then 
the back side of the cell was pressurized with CO2, by a computer-controlled 
syringe pump (ISCO 260D). The cell was immersed in a thermostated water bath 
with polycarbonate shielding.  Cloud points were determined visually by noting 
the pressure when the drug precipitated out of solution as the pressure was slowly 
reduced at 0.1 bar/sec.  Phase separation was defined as the point when a light, 
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directed into the view cell, no longer reflected off the smooth stainless steel face 
of the piston.  Each cloud point determination was repeated three times giving a 
reproducibility within ± 2 bar.  
The RESS apparatus is shown in Figure 3.1.  The solution cell consists of 
a 4 ft. long 11/16 in. I.D. by 1 in. O.D. stainless steel tube equipped with a piston.  
The cell is loaded and pressurized in a similar fashion as discussed with the phase 
behavior apparatus.  Heating tape and a temperature controller were used to 
control the temperature of the solution to within ± 0.3 °C.  The preheater 
consisted of a 16 in. long, 1/4 in. O.D. x 1/8 in. I.D. tube.  This section was heated 
with heating tape and another temperature controller.   
The nozzle consisted of a 10 in. long 1/16 in. O.D. x 0.010 in. I.D. 
stainless steel tube.  The nozzle tip was cut with a pair of wire cutters to produce a 
crimped thin slit orifice at the end of the tube.  The tapered section of the tube was 
only 0.5 mm long.  The tip was then filed back until the desired flowrate was 
achieved for a given pressure drop across the restriction.  The depressurization 
profile inside the tapered nozzle tip may be expected to be much sharper 
compared to that for a capillary tube or a 30 mm laser-drilled orifice plate.  The 
crimped nozzle never plugged with drug during the sprays, whereas plugging was 
prevalent with the 30 mm orifice.  Also, in all cases, the preheater and nozzle 
assemblies were pre-pressurized by means of a CO2 bypass line to insure there 
was no initial pressure drop inside the lines which could cause plugging.  The 
flowrate through the nozzle was compared with that through the well-defined 
laser-drilled orifice.  A 30 mm diameter orifice plate, with a thickness of 0.254 
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mm, produces a flowrate of ~5 mL/min at a DP of 345 bar.  Several different 
nozzles were made allowing flowrate ranges from 0.15 to 1.25 mL/min for the 
same DP of 345 bar, suggesting that the cross section of the orifice was 
considerably smaller than 30 mm.  Also, it was observed that the orifice was not 
circular but rather in the shape of a thin slit.  All of the experiments conducted in 
this work were performed at the same DP of 345 bar. 
The nozzle was submerged 1 cm below the surface of the aqueous 
surfactant solution, which was contained in an 80 mL, 2.2 cm diameter, side-arm 
test tube.  This was done to bring the jet, and hence the particles being formed, 
into intimate contact with the suspending medium.  The test tube was submerged 
in a temperature-controlled water bath to maintain a constant temperature within 
the trapping solution.  The temperature of the receiving solution was measured 
using a thermocouple submerged in the liquid.  The vigorous expansion of the 
CO2 spray into the aqueous solution caused considerable foaming.  To alleviate 
this problem, N2 was sprayed at 7.8 L/min and 2 bar into the tube above the foam 
through three, 1/16 in. O.D. x 0.030 in. I.D. tubes to break the foam and allow 
drainage back into the bulk liquid phase. 
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Figure 3.1.   RESS apparatus for producing suspensions of submicron, water-
insoluble drugs. 
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3.3 RESULTS AND DISCUSSION 
3.3.1 Phase Behavior 
To determine the applicability of the RESS process for micronizing certain 
drugs, their solubility in CO2 was determined.  Known amounts of drug and CO2 
were loaded into the phase behavior apparatus as described previously. The 
temperature and pressure were varied from 25-90 °C and 69-345 bar, respectively. 
The solubilities of a few hydrophobic drugs in compressed CO2 are 
summarized in Table 3.1.  The structures of these drugs are shown in Table 3.2.  
Piroxicam is only slightly soluble in CO2.  At 0.053 % (w/w), Piroxicam was 
soluble in CO2 at 331 bar and 35 °C.  0.06 % (w/w) Flurbiprofen was soluble at 
83 bar and 35 °C.  Cyclosporine A was the most soluble drug studied, with a 
solubility of up to 1.0 % (w/w) for the range of cond itions studied.  The solubility 
behavior of cyclosporine in CO2 is provided in more detail in Figure 3.2.  The 
minimum temperature required for complete solubility of 1.0 % (w/w) 
cyclosporine in CO2 was 30 °C, while lower concentrations were easily soluble  at 
room temperature.  The data show an increase in cloud point pressure with 
temperature, a characteristic of lower critical solution temperature (LCST) phase 
behavior.27  This type of behavior is entropically driven and is often observed in 
systems with supercritical fluid solvents.  Because of cyclosporine’s high 
solubility in CO2, it was chosen as the model drug for the RESS experiments.   
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Table 3.1.  Solubility of hydrophobic drugs in compressed CO2. 
Solute Concentration 
 (%, w/w) 
Temperature  
(°C) 
Cloud point 
(bar) 
Cyclosporine A 0.25 25 
30 
35 
 Soluble <83 
128 
142 
1.0 30 
50 
70 
238 
285 
330 
Flurbiprofen 0.06 35 78 
Piroxicam 0.053 35 331 
Figure 3.2.  Effect of temperature and pressure on cyclosporine A solubility in 
compressed CO2.  The drug precipitates below the cloud point 
pressure. 
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Table 3.2.  Structures of the hydrophobic drugs and surfactant used in this study. 
Compound Structure 
Cyclosporine 
MW=1201 
 Mp=148-151°C 
 
 
 
 
 
Piroxicam 
 MW=331 
Mp=198-200°C 
 
Flurbiprofen 
 MW=244 
 Mp=110-111°C 
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A 
.n increase in the amount of surfactant aids stabilization of the particle 
suspensions.  However, if the surfactant concentration becomes too large, the 
formation of a large number of micelles could lead to substantial solubilization of 
drug in the cores of the micelles.  To check this possibility, the equilibrium 
solubility of the drugs in the micellar solutions was measured as a control 
experiment.  In the next section, it will be seen that the concentrations of drug in 
the aqueous suspensions significantly exceeded the amount that dissolves in the 
micellar solutions for surfactant concentrations up to 5.0 % (w/w). 
The effects of temperature and Tween-80 concentration on the solubility 
of cyclosporine in the micellar solutions are shown in Figure 3.3. At 22 °C, the 
solubility of the drug is 0.55 mg/mL in a 1.0 % (w/w) solution and increases with 
increasing surfactant concentration to a level of 12.77 mg/mL at 20.0 % (w/w) 
surfactant.  Similarly, at 10 °C, the solubility increases from 2.1 mg/mL at 1.0 % 
(w/w) to 18.1 mg/mL at 20.0 % (w/w) surfactant.  The results indicate that the 
drug:surfactant ratio (g/g) was relatively constant with an average and standard 
deviation of 0.065 ± 0.011 at 22 °C, and 0.134 ± 0.043 at 10 °C for surfactant 
concentrations up to 5.0 % (w/w).   
To put the micellar solubilities in perspective, consider a 50 mg drug/mL 
solution.  This concentration would require drug:surfactant ratios of 4.95 in a 1.0 
% (w/w) surfactant solution, and 0.95 in a 5.0 % (w/w) solution.  These ratios far 
exceed the values for micelle solubility alone at either of the two temperatures 
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studied.  The same would be true for a 20 mg/mL solution, but at drug 
concentrations below 10 mg/mL the micellar solubility becomes significant. 
 
Figure 3.3.   Effect of temperature and concentration on solubility of cyclosporine 
A in micellar aqueous solution of Tween-80. 
 
 
 
 
 
 
 
 
 
 
3.3.2 RESS of Cyclosporine into Aqueous Solutions of Tween-80 
First, for comparison, cyclosporine processed by RESS was collected in a 
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irregular in shape when examined by scanning electron microscopy.  The rapid 
collisions between the particles in the free jet led to excessive particle growth.   
The results of spraying a 1.0 % (w/w) solution of cyclosporine in CO2 into 
a 1.0 % (w/w) aqueous solution of Tween-80 are summarized in Table 3.3. The 
cyclosporine in CO2 solution was again held at a temperature of 30 °C.  In all 
cases, the pre-expansion temperature and pressure were 60 °C and 345 bar.  At 
this condition, the cyclosporine was completely soluble as determined in Figure 
3.2.  The receiving solution was heated to maintain a constant temperature of 25 
°C.  The pre-expansion temperature and the receiving solution temperature were 
chosen to prevent water from freezing at the tip of the nozzle. 
Table 3.3 is organized in order of increasing drug:surfactant ratio.  A 
minimum ratio of approximately 0.065 is required to be above the micellar 
solubility of the drug at 25 °C.  The concentration shown is the measured amount 
of drug in the suspension according to HPLC.  In each run, a measured volume of 
a known concentration of cyclosporine in CO2 was sprayed.  Hence, the yield is 
the percentage of the recovered drug, according to HPLC, relative to the amount 
of drug sprayed.  The particle size range as measured by DLS is also given in 
Table 3.3. Before addition of the cyclosporine, the Tween-80 micellar solutions 
were clear, and hence the micelles were too small to scatter light and were not 
measurable by DLS. 
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Table 3.3. Cyclosporine microparticles prepared by RESS of a 1.0 % (w/w) 
solution into 20.0 mL of 1.0 % (w/w) Tween-80 aqueous solution.  
Tsol’n = 30.0 °C, Tpreheater = 60.0 °C, DP = 345 bar. 
 
 
 
# 
Solution 
Flowrate 
(mL/min) 
Spray 
Time 
(min) 
Drug 
Concentration 
(mg/mL) 
Yield 
(%) 
Particle 
Size 
(nm) 
Drug:Surfact
-ant Ratio 
1 0.25a,b 15 2.93  230-4100  
2 0.35 6.5 0.91 82 410-540 0.090 
3 0.31 16 2.08 86 420-560 0.206 
4 0.51c 20 3.09 63 250-890 0.306 
5 0.35 29 5.92 100 410-600 0.586 
6 0.56 18 6.20 100 440-670 0.614 
7 0.20b 141 17.60 66 440-1600 1.74 
 
a  No surfactant present 
b 10.0 mL receiving solution 
c Foam overflowed leading to low yield 
 
 
As a control experiment (1), the drug solution was sprayed into pure 
water.  In this case, the aqueous phase became slightly turbid and also foamed.  
Spraying pure CO2 into H2O does not cause foaming; thus cyclosporine is surface 
active at the H2O-CO2 interface.  According to the DLS measurements, the 
particles ranged in size from 230 to 4100 nm, as there is no surfactant present to 
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provide stabilization.  Significantly larger particles were also observed visually, 
which were too large for measurement by DLS.   
Cyclosporine in CO2 was sprayed into 1.0 % (w/w) Tween-80 solutions to 
attempt to stabilize submicron particles.  In experiment (2) the drug:surfactant 
ratio was 0.090 mg/mL, and the stabilized particles ranged in size from 410-540 
nm.  In this case, the foaming was adequately controlled, and the yield was 
approximately 82%.  This experiment, with a low drug loading, demonstrates that 
the initial small particles can be stabilized within the expanding jet, without 
excessive growth due to particle collisions, unlike the cases where there was no 
trapping solution or surfactant stabilizer. 
The suspensions in experiments (2), (3), and (5) were formed by spraying 
at a constant flowrate but for increasing amounts of time to achieve higher drug 
loadings. Significant change in the particle size distribution was not observed as 
the drug loading was increased from 0.91 to 5.92 mg/mL, indicating the surfactant 
limits particle growth.  Also, the yield was high in all cases, suggesting that the 
drug was not entrained by the rising gaseous CO2.  Experiments (4) and (6) were 
conducted at higher flowrates for the same DP with a larger nozzle slit.  In 
experiment (4), some overflowing of the foam occurred and led to a lower drug 
trapping efficiency and a broader particle size distribution due to less thorough 
surfactant stabilization.  A comparison of (5) and (6) demonstrates that increasing 
the flowrate from 0.35 to 0.56 mL/min does not have a significant impact on the 
particle size, for similar aqueous drug concentrations.  In all of these examples, 
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the surfactant diffuses rapidly enough to the particle surfaces to prevent excessive 
growth. 
In most cases, submicron particles were stabilized even at the higher drug 
loadings.  In some cases, extreme foaming caused surfactant depletion and 
resulted in broader particle size distributions, for example in (4).  The reason for 
the foam overflow was insufficient N2 flow to break the foam, a problem that was 
easily overcome in the other experiments.  Also, in cases where the drug 
concentration was very high, like (7), the number of particle collisions in the 
aqueous solution was high, leading to larger particle sizes.  Furthermore, the 
surfactant levels available to adsorb to particle surfaces decrease as the 
drug:surfactant ratio reaches 1.74.  Concentrations of drug in 1.0 % (w/w) Tween-
80 solutions as high as 6.20 mg/mL could be stabilized with particle diameters in 
the range of 500 nm.  With a higher drug loading and drug:surfactant ratio, size 
distributions became broader.  It was observed that the surfactant level was 
insufficient to stabilize the particles for a drug:surfactant ratio significantly above 
0.6.  
Table 3.4 summarizes the results of spraying 1.0 % (w/w) solutions of 
cyclosporine in CO2 into more concentrated 5.0 % (w/w) aqueous Tween-80 
solutions.  The drug levels ranged from 3.97 to 45.9 mg/mL.  The pressure of the 
solution was held at 345 bar and several flow rates were studied by using different 
nozzle sizes.  The higher surfactant concentration in these cases led to 
stabilization of submicron particles (~500 nm) at concentrations of up to 37.5 
mg/mL at a drug:surfactant ratio of 0.713.  Experiments (9) - (11) demonstrate 
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reasonable reproducibility for these experiments.  Also, a comparison of (5) from 
Table 3.3 with (9) – (11) in Table 3.4 indicates the change in particle size is 
insignificant when changing from 1.0 to 5.0 % (w/w) surfactant solutions. At drug 
loadings of ~ 6 mg/mL both solutions can stabilize the particles.  Drug 
concentrations in the suspensions as high as 37.5 mg/mL could be stabilized 
efficiently in a 5.0 % (w/w) Tween-80 solution, as seen in (13).  Such high 
concentrations could not be achieved in a 1.0 % (w/w) solution, because the 
drug:surfactant ratios become excessive for particle stabilization. 
The significantly higher flowrate in (8) seems to produce smaller particles 
than in (9) and (10).  This is possibly due to several factors: more vigorous 
stirring within the receiving cell due to the high-velocity CO2 stream, a change in 
expansion characteristics due to the larger nozzle slit used for the higher flowrate, 
and/or the lower drug loading and drug:surfactant ratio.  In (12) and (14), the 
lower trapping efficiency is a result of spraying into only 10 mL of the trapping 
solution.  While the foam produced during the spray was suppressed, i.e. kept at a 
constant level so as to avoid overflowing, it was not completely eliminated.  
Therefore, a greater percentage of the surfactant and H2O were lost to the foam 
for an initial 10 mL of solution compared to 20 mL, since the foam heights were 
equal. However, the particle size was not affected by changing the receiving 
solution volume, only the yield.  At a drug loading higher than 37.5 mg/mL, the 
particles were stabilized much less effectively, as seen in (14).  In this case, the 
drug:surfactant ratio was up to 0.873 and the particle size distribution was broad.  
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As in the experiments shown in Table 3.3, the particle size distribution becomes 
much broader above a threshold drug:surfactant ratio of about 0.6-0.7. 
Table 3.4. Cyclosporine microparticles prepared by RESS of a 1.0 % (w/w) 
solution into 20.0 mL of 5.0 % (w/w) Tween-80 aqueous solution.  
Tsol’n = 30.0 °C, Tpreheater = 60.0 °C, DP = 345 bar. 
# 
Solution 
Flowrate 
(mL/min) 
Spray 
Time 
(min) 
Drug 
Conc. 
(mg/mL) 
Yield 
(%) 
Particle 
Size 
(nm) 
Drug:Surfactant 
Ratio 
8 1.25 8 3.97 82 15-560 0.075 
9 0.57 19 5.55 95 340-500 0.105 
10 0.55 19 5.58 99 490-600 0.106 
11 0.56 20 6.10 96 410-520 0.116 
12 0.24 a 112 23.8 64 410-545 0.452 
13 0.55 70 37.5 100 500-660 0.713 
14 0.37 a 122 45.9 64 380-550, 
970-1550b 
0.873 
a 10.0 mL receiving solution 
b Two peaks - 37% in lower peak by intensity averaging, 63% in lower 
peak by weight 
3.4 CONCLUSIONS  
Aqueous stabilizing solutions have been successfully incorporated into the 
RESS process to trap 500 nm particles of a water-insoluble pharmaceutical 
compound.  In RESAS, the surfactant diffuses rapidly to the particle surface to 
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impede particle agglomeration and growth.  Cyclosporine microparticles were 
formed by spraying a 1.0 % (w/w) solution (in CO2) into 1.0 and 5.0 % (w/w) 
Tween-80 solutions to prevent microparticle flocculation and agglomeration.  By 
RESAS, cyclosporine particles 500-700 nm in diameter were stabilized for drug 
concentrations as high as 6.20 mg/mL and 37.5 mg/mL in 1.0 and 5.0 % (w/w) 
Tween-80 solutions, respectively.  At a drug:surfactant ratio above 0.6-0.7 the 
surfactant can no longer stabilize the particles, resulting in broader size 
distributions.  RESAS may be expected to be a general process to produce smaller 
particle sizes of organic and inorganic water-insoluble materials than in the case 
of RESS into air.  
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CHAPTER 4 
Phopholipid-Stabilized Nanoparticles of Cyclosporine A by Rapid 
Expansion from Supercritical to Aqueous Solution 
4.1 INTRODUCTION 
The often low bioavailability of water- insoluble drugs leads to poor 
pharmacokinetic performance in the body.  Techniques to improve bioavailability 
in oral or parenteral applications of water-insoluble drugs include powder 
micronization, the formation of micron- and submicron-size dispersions, and 
solubility enhancement in aqueous solution by addition of appropriate surfactants, 
organic solvents or buffers, or drug-carrier systems such as liposomes.  The 
payloads for drugs in liposomes are often limited due to the low volume fraction 
of hydrophobic regions.1 The use of surfactants or organic solvents in parenteral 
administration can lead to phlebitis, anaphylaxis, hypotension, or even 
vasodilation.1  Traditional micronization techniques such as spray-drying2,3, 
emulsion-solvent extraction4-6, and processes based on high shear, for example, 
microfluidization, high-pressure homogenization, ball milling, and air jet milling7-
11 can have certain drawbacks.  With many of these techniques, particle size 
distributions tend to be broad, products can be denatured by exposure to high 
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temperatures or organic solvents, residual solvent concentrations can be high 
without lengthy periods for additional extraction/evaporation, or undesirable 
processing agents will need to be separated from the final products.  Yields can be 
well below 100% due to losses in solids handling in milling and spray drying.  
Milling techniques also require cumbersome solids handling.  Hence, processing 
techniques that do not rely on organic solvents, high temperatures, and that can 
provide small particles with narrow distributions are highly desirable.   
Dissolution rates of poorly-water soluble drugs may be increased by 
reducing the particle size, to increase the surface area, and by inhibiting 
crystallization to form amorphous particles.  Both of these factors may be 
achieved by phase separation techniques that include rapid nucleation rates and 
prevention of particle growth.  The process rapid expansion from supercritical 
solution (RESS) may be used to accomplish these goals according to theoretical 
models of nucleation.  The expansion from the supercritical state to atmospheric 
pressure reduces the solvent density (or strength) and initiates intense 
nucleation.12-22  The particle formation steps include nucleation, condensation of 
solute molecules about the nuclei and coagulation of particles in the free jet 
expansion.  Recent work by Charoenchaitrakool et al.23 has produced 2.5 mm 
particles by RESS with enhanced dissolution rates for the poorly water-soluble 
compound ibuprofen, likely due to both the reduction in particle size and 
crystallinity.23  If coagulation can be minimized, it should be possible to produce 
20-50 nm drug particles.24,25     
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A novel process, rapid expansion from supercritical to aqueous solution 
(RESAS) has been developed to reduce the coagulation rate in the free jet 
expansion of RESS.26  The supercritical solution is expanded through an orifice or 
tapered nozzle into an aqueous solution containing a stabilizer to minimize 
particle aggregation during free jet expansion.  Previously, Young, et al. 
demonstrated the ability for Tween 80, a non- ionic polysorbitan ester, to stabilize 
400-700 nm cyclosporine particles produced by RESAS.26  CO2 was chosen as the 
supercritical fluid of interest since it is an environmentally benign solvent that is 
nonflammable, inexpensive, and essentially non-toxic.  It also has relatively mild 
critical conditions, Tc = 31 °C, Pc = 73.8 bar, and so allows processing at 
moderate temperatures to prevent thermal degradation.  Sun, et al. have 
demonstrated a technique to form PbS nanoparticles by expanding a supercritical 
fluid containing one reactant, Pb(NO3)2, into a liquid solution containing a second 
reactant, Na2S.27 
Here, we focus on phospholipids to minimize coagulation in RESAS.  
Phospholipids are amphiphilic molecules, usually consisting of two lipophilic 
tails, which, when added to water, rapidly aggregate and form liposomes.  
Depending on the chemical compositions of the phospholipids, concentration, and 
method of formation, a variety of sizes and structures can be formed such as 1-10 
mm multi- lamellar vesicles (MLVs), 0.1-1 mm large unilamellar vesicles (LUVs), 
and <0.1 mm small unilamellar vesicles (SUVs).28,29  In this work, the focus is on 
SUVs.  High drug:lipid ratios with particle sizes <1 mm have been achieved by 
micronizing drugs while in the presence of phospholipid stabilizers.1  It is 
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suggested that in these systems the drug not only partitions into the bilayers of the 
SUVs employed, but colloidal drug particles are stabilized by a monolayer of 
phospholipid and either successive bilayers or small loosely associated vesicles.  
The goal of this work was to use phospholipid vesicle solutions to stabilize 
nanoparticle aqueous dispersions of cyclosporine, a water- insoluble 
immunosuppressant, with substantial payloads, e.g. above 20 mg/mL by RESAS.  
To place these experiments in perspective, we begin by presenting briefly new 
RESAS results for stabilization by a series of micelle-forming surfactants 
(without phospholipids).  We then demonstrate that higher drug loadings and 
smaller drug particles (<500 nm) may be produced with the phospholipid vesicles.  
The phospholipids are mixed with small amounts of micelle- forming surfactants 
to enhance fluidity of the surfactant bilayers.  The results are compared for 
aqueous solutions stabilized with vesicles with only micelle- forming surfactants 
to provide mechanistic insight into the stabilization processes.  The effects of 
several variables, such as drug concentration in the suspension, stabilizing 
solution temperature, preheater temperature, and flowrate are examined.  The 
products are evaluated by measuring drug loading with high performance liquid 
chromatography (HPLC), particle sizing by dynamic light scattering (DLS), and 
particle morphology by transmission electron microscopy (TEM) and x-ray 
diffraction. 
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4.2 EXPERIMENTAL 
4.2.1 Materials and methods .   
Cyclosporine was obtained from North China Pharmaceutical Corporation 
and used without any further purification.  Lipoid E80 (Vernon Walden, Inc.)  
Phospholipon 100H (American Lecithin Co.), Myrj 52 (ICI Americas), Pluronic 
F127(BASF), methanol (HPLC grade, EM Science), and Tween 80 (Aldrich) 
were used without further purification.  Mannitol, sodium lauryl sulfate, and 
sodium deoxycholate were purchased from Sigma and used without further 
purification.  Water was purified to Type I reagent grade by passing it through a 
Barnstead (NANOpure II) filtration system.  Instrument grade CO2 (Matheson) 
was used for all of the experiments.  The structures of the various surfactants used 
in this study are shown in Table 4.1. 
High performance liquid chromatography (HPLC) combined with UV 
detection was used to quantify the drug concentration from the aqueous 
suspensions.  The column used for HPLC was a 250 mm long C-18 column (SGE 
ODS, 5 mm).  Samples were prepared by withdrawing 0.5 mL of the suspension 
and adding to 5 mL of methanol, of which 9.6 mL was actually injected onto the 
column.  The mobile phase consisted of pure methanol, and the detection 
wavelength was 210 nm.   
The solubility of cyclosporine in the surfactant solutions was determined 
from a saturated solution at 25 °C.  Excess drug was added to 10 mL of each 
surfactant solution and allowed to equilibrate with stirring for 1 week at 25 °C.  
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The dissolved drug content was determined by the above-mentioned HPLC 
method by analyzing a filtrate of each saturated solution. 
The intensity-weighted particle size distribution was determined by 
Dynamic Light Scattering (DLS) via a Brookhaven Zetaplus (Brookhaven 
Instruments Corporation, New York).  Particle size measurements were made 
within 24 hours of preparation and at 1-month time intervals.  Multimodal size 
distributions were determined by a non-negative least squares method and the 
mean diameters and size ranges reported. 
87 
Table 4.1.  Structures of the surfactants used in this study. 
Surfactant Structure 
Myrj 52 
Pluronic F127 
Tween 80 
SLS 
CH3 (CH2)16
O
(OCH2CH2)40 OH
HO(CH2CH2O)98(CH2CHO)67(CH2CH2O)98H
CH3
O
(OCH2CH2)
CH
C
H2
(OCH2CH2)
(OCH2CH2)
XOH
HO(CH2CH2O) W
YOH
zO COR
R= CH3(CH2)7CH CH(CH2)7-
W+X+Y+Z=20
CH3(CH2)10CH2 O S O
O
O
Na
+
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X-ray diffraction data was taken with a PW1720 X-ray generator (Philips).  
Suspensions examined were frozen, lyophilized, and the dry powder remaining 
was examined.  Samples containing liquid surfactants, like Tween 80, could not 
be examined by this technique, only those that form a dry powder. 
Differential scanning calorimetry was used to determine the phase 
transitions of the phospholipids.  A TA Instruments DSC 2920 calorimeter was 
used.  Typically, 8-15 mg of sample was loaded into the pan.  A heating rate of 1 
°C/min was used to scan over the temperature range desired. 
Confirmation of vesicle and particle size and structure was determined by 
transmission electron microscopy using a Philips EM208 microscope.  Diluted 
samples were dropped onto copper grids coated with Formvar.  The grid was 
allowed to stand for 5 minutes, before the negative stain was dropped onto the 
grid.  The stain used was a 1.0 % (w/w) solution of uranyl acetate, which had 
been brought to a neutral pH to prevent damage to vesicle structure.30   After 
staining for 5 minutes, the grid was washed lightly (3 drops) with pure water and 
then the excess water was removed by touching the edge of the grid to an 
absorbent cloth. 
 
4.2.2 Preparation of phospholipid vesicles.   
Phospholipid solution “A” was typically made with an overall aqueous 
batch size of 200 g.  First, Tween 80 and mannitol were added to the requisite 
amount of water and stirred until completely dissolved.  The solution was chilled 
in an ice water bath, and then the phospholipid added.  The solution was stirred 
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and sonicated (Branson Sonifier 250) while still chilled to break up any large 
clumps.  At this time the pH was adjusted to 7.0 by adding 0.1 M NaOH.  This 
solution was then passed 30 times through a high-pressure homogenizer (Avestin 
Emulsiflex C-5) at a shear pressure drop of 15000 psig to produce small 
unilamellar vesicles.  The outlet flow from the pump was passed through a 
chilling tube, which was submerged in an ice bath, before returning to the pump 
feed supply to keep the temperature of the phospholipid solution entering the 
pump at 10 °C.  At the end of the run, the pH was again checked and, if 
necessary, 0.1 M NaOH was added to bring the final pH to between 7.5 and 8.0.  
This solution was then refrigerated at 4 °C until ready for use. 
4.2.3 Rapid Expansion from Supercritical to Aqueous solution.  
The RESAS apparatus is shown in Figure 4.1.  The carbon dioxide was 
supplied to the system by means of a high-pressure computer-controlled syringe 
pump (ISCO).  The two solution cells are comprised of 4 ft long, 11/16 in. i.d. x 1 
in. o.d. stainless steel tubes set up in parallel and equipped with pistons.  Each cell 
was loaded with a predetermined mass of drug above the piston, sealed, and then 
loaded with a known volume of CO2.  The back side (or bottom) of the piston was 
subsequently pressurized by CO2 to the desired pressure.  Each cell was heated by 
4, 2’ long strips of heating tape connected to heating controllers to maintain the 
temperature to within ± 0.3 °C.  For initial solution equilibration and mixing, only 
2 of the heating tape strips were heated (the second and fourth from the top) to 
produce density fluctuations within the fluid to aid mixing.  At the same time, the  
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Figure 4.1.      Schematic of apparatus used for rapid expansion from supercritical 
to aqueous solution (RESAS). 
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pressure within the cell was cycled via the syringe pump to create further mixing 
by moving the piston up and down.  Typically, the solution would come to the 
equilibrium concentration within 24 hours.  The solution concentration was 
checked by spraying the solution into pure methanol to collect dissolved drug, and 
the sample was analyzed by HPLC.  If the aforementioned mixing technique was 
not utilized it could take the solution up to a week to reach equilibrium.  The 
preheater consisted of a 30 ft. long piece of 1/16 in. o.d. x 0.03 in. i.d. stainless 
steel tubing coiled within a 1 ½” dia. x 20” long tube (column heater - Alltech) 
with heated water circulating through it at a rate of 2.4 L/min.  This allowed very 
uniform heating of the preheater coil, preventing hot spots, which could otherwise 
produce crystallization of the drug within the coil.   
For most of the experiments, the nozzle was made from a 10 inch long, 
1/16 in. o.d. x 0.03 in. i.d. stainless steel tube, in a similar manner to that 
previously described. 26   Two sizes of nozzle were made by filing the end of the 
nozzle, allowing flowrates of 0.88 mL/min or 2.5 mL/min at a constant pressure 
drop of 345 bar.  Figure 4.2 provides an example of what the spray pattern looks 
like exiting the 2.5 mL/min nozzle operated at a pressure drop of 345 bar.  For 
comparison purposes, a 10 in. long piece of 50 mm i.d. fused silica capillary 
tubing (Polymicro Technologies, Inc.) was used as the nozzle for a few 
experiments.   
The aqueous stabilizing solution was held in a 125 mL separatory funnel.  
The expanding diameter of the funnel helps to destabilize foam formation created 
by CO2 bubbling through the solution, while providing sufficient depth for small  
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Figure 4.2     Spray profile for a CO2 solution expanding through a tapered 
elliptical nozzle with a flow rate of 2.5 mL/min at 345 bar. 
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volumes of liquid to allow the nozzle to be submerged.  The nozzle was 
submerged approximately 1 cm below the surface of the aqueous solution.  In this 
way, the particles that are being formed are brought into close contact with the 
stabilizing solution.  The separatory funnel was submerged within a temperature-
controlled water bath.  A thermocouple was submerged next to the nozzle in the 
stabilizing solution to measure the local temperature of the solution.  To suppress 
and drain any foam produced during RESAS, N2 gas was blown down on top of 
the foam at 7.8 L/min and 2 bar into the funnel approximately 4 cm above the 
foam through four, 1/16 in. o.d. x 0.03 in. i.d. stainless steel tubes.  Prior to each 
experiment, 10 mL of the stabilizing solution was filtered with a 0.2 mm PES 
sterile disposable syringe filter (Whatman) and then added to the funnel.  
Immediately prior to collecting the particles, the stabilizing solution in the funnel 
was submerged in the heated water bath to bring it to the desired collection 
temperature.   
To produce the suspensions, first the preheater and nozzle assemblies were 
prepressurized with CO2.  The prepressurization prevented plugging of the nozzle.  
Once the flow of CO2 had equilibrated, the flow was switched so as to push the 
solution out of the cell and through the nozzle.  Initially, the spray was conducted 
by spraying into a separatory funnel containing pure water.  Once drug particles 
began to accumulate in the water, the separatory funnel was switched to one of 
the prepared and preheated stabilizing solutions.  A measured volume (as 
measured by the syringe pump) of solution was sprayed to produce a suspension 
of a desired concentration.  Upon completing the spray, the stabilizing solution 
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was replaced by pure water again, and the flow switched back to pure CO2.  
Sufficient CO2 was allowed to spray through the nozzle to insure all drug was 
swept out of the system to prevent nozzle plugging upon depressurization.  For all 
of the samples using phospholipid-based surfactants the pH of the suspension was 
adjusted again, after the spray was completed, to 7.0 by adding sufficient 0.1 M 
NaOH.  Typically the pH of the phospholipid solution would go from 7.5 ® 3.5 
during the course of the spray.  pH neutralization was required to insure long-term 
stability of the phospholipids.  The samples were stored with a N2 headspace by 
purging the air from the sample vial through a septum in the vial cap to prevent 
oxidation of the phospholipid components.  The samples were refrigerated at 4°C. 
4.3 RESULTS AND DISCUSSION 
4.3.1 Cyclosporine solubility.  
The phase behavior of cyclosporine in CO2 has previously been reported. 
26 At 30 °C and 345 bar, 1.0 % (w/w) of cyclosporine is readily soluble in CO2.  
All of the RESAS experiments in this work were performed with an initial 
solution concentration of 1.0 % (w/w).  It is important to note that the solubility of 
cyclosporine in CO2 decreases with temperature at constant pressure (cloud point 
increases).  The solubilities of cyclosporine in the surfactant solutions used for 
stabilization were measured to serve as a control, as shown in Table 4.2 at 25 oC.  
The goal of RESAS was to produce suspensions with a drug/surfactant ratio much 
higher, and at least twice as high, as is obtained from the equilibrium solubility in 
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the surfactant solution.  As a result, SLS was not chosen as one of the surfactants 
to examine since the solubility of cyclosporine in this solution is quite high.   
 
Table 4.2.  Solubility of cyclosporine in various surfactant systems at 25.0 °C. 
 
Surfactant name Surfactant conc. in 
H2O 
Drug 
solubility 
Drug/surf. 
ratio 
 % (w/w) mg/mL w/w 
Tween 80a 1 0.56 0.056 
 2 1.2 0.060 
Myrj 52 2 1.7 0.085 
SLS 2 27.0 1.4 
Pluronic F127 2 0.01 0.0005 
Lipoid E80/Tween 
80/mannitol 
10/2/5.5 4.75 0.04 
 1/0.2/0.55 0.32 0.03 
a Young, et al. Biotechnol. Prog., 2000, 16(3), 402-7 
 
4.3.2 Effect of surfactant type on particle size.   
While the bulk of the RESAS experiments will focus on phospholipid-
based systems, micelle-forming surfactants including Tween 80, Poloxamer F127, 
and Myrj 52 were studied for comparison, as shown in Table 4.3.  All of the 
experiments conducted in the table had the following initial conditions:  a drug 
concentration of 1.0 % (w/w) in CO2, a solution temperature of 30.0 °C, a 
preheater temperature of 60.0 °C, a pressure drop of 345 bar with a nozzle that  
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Table 4.3.   Effect of surfactant type on cyclosporine microparticles prepared by 
RESAS of a 1.0 % (w/w) solution into 10.0 mL of 2.0 % (w/w) 
aqueous surfactant solution.a 
Surfactant 
type 
Drug 
conc. 
(mg/mL) 
Yield 
% (w/w) 
Particle 
mean 
(nm) 
Particle size 
distribution 
(nm) 
Drug/surf. 
ratio 
@ max sol. 
Drug/surf. 
ratio 
(g/g) 
Tween 
80b 
6.1 68 970 210-320(21%), 
500-760(59%), 
2200-3400(20%) 
0.056 0.61 
Tween 
80b 
5.4 64 660 220-290(25%), 
700-940(75%) 
0.54 
F127 4.0 46 1010 140-250(12%), 
400-860(75%), 
3400-5400(13%) 
0.0005 0.20 
F127 4.7 48 1200 180-310(7%), 
520-870(66%), 
2100-4100(27%) 
0.24 
Myrj 52 4.6 49 840 90-120(2%), 
310-590(58%), 
1100-2100(40%) 
0.085 0.23 
Myrj 52 3.2 38 1240 150-270(9%), 
410-850(79%), 
4800-7500(13%) 
0.16 
SLS ------ ------ ----- ------- 1.4 
a Tsol’n =  30.0 °C, Tpreheater = 60.0 °C, DP = 345 bar, Tbath = 25.0 °C, solution flowrate = 
2.5 mL/min 
b 1.0 % (w/w) 
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produced a flow rate of 2.5 mL/min, and a stabilizing solution bath temperature of 
25 °C.  The table shows the final concentration of drug in the suspension as 
measured by HPLC, the mean particle size, the particle size distribution (with the 
relative percentage of particles found in each peak for multi-peak distributions), 
and the drug to surfactant ratio for the equilibrium solubility as well as for the 
actual suspension.     
As seen in Table 4.2, Tween 80 stabilized particles with mean diameters 
from 660 – 970 nm with fairly broad distributions at relatively high 
drug/surfactant ratios of nearly 0.6, which was 10 times the equilibrium solubility.  
These results agree reasonably well with previous work.26   The new experiments 
utilize smaller aqueous stabilizer volumes and higher flow rates that did not seem 
to modify the particle size.  To minimize aggregation resulting from particle 
collisions, the surfactant must reach the surface of the primary particle rapidly and 
orient such that it can provide steric stabilization.  Previously,26 the particle size 
increased markedly for a drug:surfactant ratio >0.6, due to insufficient surface 
coverage.  In contrast, using Pluronic F127 led to substantially larger particles, 
despite the lower drug/surfactant ratio of approximately 0.25.  It appears that this 
surfactant has a lower affinity for the particle surface, which would be consistent 
with the low equilibrium solubility.  The lipophilic propylene oxide group makes 
up only 30 % (w/w) of the surfactant molecule, which might not be enough for 
sufficient adsorption at the particle surface.  The use of Myrj 52 also yielded 
larger cyclosporine particles than Tween 80.  While this surfactant has a modestly 
different lipophilic group than Tween (stearate compared to oleate), it also has a 
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more linear, or less bulky, hydrophilic group.  Tween 80 has several ethylene 
oxide side chains providing greater steric repulsion in the continuous aqueous 
phase.  
 
Table 4.4.   Compositions of the various phospholipid surfactant systems used in 
this study. 
 
Designation Components  Concentrations 
% (w/w) 
Vesicle 
size mean 
nm 
Vesicle 
size range 
nm 
     
Phospholipid 
“A” 
Lipoid E80/ Tween 80/ 
Mannitol 
10/2/5.5 
1/0.2/0.55 
39.6 
35.1 
20-50 
10-50 
Phospholipid 
“B” 
Phospholipon 100H/ 
Tween 80/ Mannitol 
2/2/5.5 90.2 70-280 
Phospholipid 
“C” 
Phospholipon 100H/ 
Myrj52/ Sodium 
Deoxycholate/ Mannitol 
2/1/0.25/5.5 131.2 60-360 
Phospholipid 
“D” 
Phospholipon 100H/ 
Myrj52/ Mannitol 
2/2/5.5 140.5 70-440 
 
Results are shown in Table 4.5 for several phospholipid-based surfactant 
mixtures, whose compositions are given in Table 4.4.  The two phospholipids 
included commercially available compounds Lipoid E80 (from chicken egg-
white) and Phospholipon 100H (hydrogenated soybean), which both consist 
primarily of dipalmitoylphosphatidylcholine (DPPC), and include small amounts 
of impurities such as phosphatidylethanolamine, sphingomyelin, and lyso-
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phosphatidylcholine.  Each of these systems was prepared so as to have initial 
structures consisting of small unilamellar vesicles < 1 mm in water.  Preparations 
made with Lipoid E80 had starting vesicle sizes of 10-50 nm, while those made 
with Phospholipon 100H were slightly larger, as confirmed by DLS.  The 
nonionic surfactants can act to make the vesicle bilayer more fluid31, facilitating 
transport across the bilayer.  All of these systems included Mannitol to enhance 
vesicle stability, and also to act as a cryoprotectant to prevent loss of structure 
during lyophilization.32-34   Sodium deoxycholate was utilized in system “C” to 
supplement the steric stabilization with electrostatic stabilization. 
Results are shown in Table 4.5 for the various phospholipid-based 
surfactant systems.  The table shows the final concentration of drug in the 
suspension as measured by HPLC, the mean particle size, the particle size 
distribution (with the relative percentage of particles found in each peak for multi-
peak distributions), and the drug to surfactant ratio for the equilibrium solubility 
as well as at the final suspension concentration.  In order to be able to distinguish 
between vesicles and particles in the final solutions, a few control experiments 
were performed.  First, in the range of 10 – 50 °C, it was found that the size of the 
SUVs does not change when measured by DLS.  Second, if pure CO2 is sprayed 
into the solution for a time similar to that in the rest of the experiments (up to an 
hour), there is also no change in the vesicle size even with the change in pH from 
7 ® 3 that results.  pH is known to affect vesicles by increasing DPPC hydrolysis 
rates, and pH gradients have been utilized in the formation of SUVs.35  Therefore, 
it’s reasonable to  
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Table 4.5.   Effect of surfactant type on cyclosporine microparticles prepared by 
RESAS for a stabilizing solution bath temperature of 25 °C.a 
Phospholipid 
surfactant 
composition 
Drug 
conc. 
(mg/mL) 
Yield 
% (w/w) 
Particle 
mean 
(nm) 
Particle size 
distribution 
(nm) 
Drug/surf. 
ratio 
(g/g) 
Ab 6.5 93 220 30-50(4%), 
100-160(66%), 
330-560(30%) 
0.54 
Ab 6.9 100 220 80-120(32%), 250-
300(68%) 
0.58 
B 4.6 54 660 80-420(91%), 
3300-6300(9%) 
0.12 
B 5.1 62 640 80-420(93%), 
5100-7100(7%) 
0.13 
C 4.1 26 2740 140-300(16%), 
720-1740(60%), 
7500-10000(34%) 
0.13 
C 4.2 34 4110 280-470(56%), 
7700-10000(44%) 
0.13 
D 7.7 63 390 150-200(54%), 
560-750(46%) 
0.19 
D 6.9 59 460 110-180(54%), 
320-560(27%), 
1180-2060(19%) 
0.17 
a Tsol’n =  30.0 °C, Tpreheater = 60.0 °C, DP = 345 bar, Tbath = 25.0 °C, solution flowrate = 
2.5 mL/min 
b 1.0 % Lipoid E80/ 0.2 % Tween 80/ 0.55 % Mannitol (w/w); Tbath = 45.0 °C
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believe that any change in particle size distribution as measured by DLS after 
RESAS with a drug would correspond to the presence of stabilized drug particles.     
The low concentration solution “A” was able to stabilize cyclosporine 
particles at concentrations of ~7 mg/mL (~0.6 drug:surfactant ratio) with mean 
diameters of 220-230 nm and relatively narrow size distributions as seen in Table 
4.5.  The distributions are bimodal.  The smaller peak is somewhat larger than the 
initial drug-free vesicles suggesting that the drug induces modest aggregation of 
these vesicles.  The larger peak is 5-10 times the size of the initial vesicles.  It is 
likely that most of the drug is contained in these larger aggregates.  The 
drug/surfactant ratios are over 20 times the equilibrium solubility in the vesicles.  
While the examples discussed here were made with the lower concentration of 
formulation A, these suspensions tended to be less stable (discussed in more detail 
later) and were incapable of stabilizing drug payloads up to 50 mg/mL.  
Therefore, the majority of the rest of the work detailed herein was conducted 
using the higher concentration of formulation A.   
Figure 4.3 shows TEM micrographs taken of several of the suspensions 
formed in this study.  The top picture shows the initial empty SUVs of 
phospholipid formulation A before RESAS with particle sizes that are between 
10-80 nm.  Upon exposure of the aqueous vesicles to CO2, there was no 
noticeable change in the TEM micrographs.  Note that in some regions, the 
vesicles associate loosely to form aggregates.  Also, the vesicle shape appears 
distorted from a spherical shape.  Some distortion can occur due to collapse or 
close packing of the vesicles upon water evaporation.28,35   The negative staining  
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Figure 4.3    TEM micrographs of: a) initial SUVs made from phospholipid formulation 
A before RESAS, b) drug loaded vesicles of phospholipid formulation A at 
a concentration of 17.6 mg/mL and stabilizing solution temperature of 31.1 
°C; operating conditions: Tsoln = 30.0 °C, Tpreheater = 60.0 °C, DP = 345 bar, 
Tbath = 45.0 °C, solution flowrate = 2.5 mL/min, c) drug loaded vesicles of 
phospholipid formulation A at a concentration of 54.0mg/mL and 
stabilizing solution temperature of 50.3 °C; operating conditions: Tsoln = 
30.0 °C, Tpreheater = 60.0 °C, DP = 345 bar, Tbath = 80.0 °C, solution flowrate 
= 2.5 mL/min 
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technique can be used to observe multilamellar structures, if present.   MLVs 
could be seen (not shown) before homogenization to form SUVs.  The middle 
micrograph shows the particles at a drug:surfactant ratio of 0.15, showing both the 
large stabilized drug particles (~200 nm) as well as small vesicles.  The DLS 
results showed particles as large as 400 nm, so there may be some aggregation 
occurring within the suspension between the larger drug particles and the 
remaining SUVs.  Unfortunately, with this staining technique, we were unable to 
visualize the monolayer of surfactant on the particles, as the stain simply deposits 
around the outside of the particle.  Also, we saw no evidence of successive 
bilayers surrounding the particles.  While it was somewhat difficult to distinguish 
between drug particles and vesicles, the larger objects seen in this micrograph 
never appeared when inspecting phospholipid vesicles with no drug.  Also, the 
entities we believe to be the drug particles have highly non-uniform surfaces, 
which was also something not observed with unloaded vesicles.  The bottom 
micrograph shows the particles formed at a high drug:surfactant ratio of 0.45, 
depicting very few small vesicles remaining with numerous large stabilized drug 
particles, approaching 300 nm.  The DLS results in this case indicated three size 
ranges, 40-60, 100-200, and 500-920, with the bulk of the material present in the 
last peak.  This distribution again suggests that some of the particles in the TEM 
associate or aggregate.  
The particle diameters of the phospholipid-stabilized suspensions are 
markedly lower than those produced with micellar- forming surfactants for similar 
surfactant concentrations and drug/surfactant ratios.  To stabilize such small 
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particles, the surfactant must be able to rapidly adsorb onto the particle surfaces as 
they precipitate and hinder growth in the jet.  Since the bulk of the surfactant is 
now in the structure of a vesicle, the stabilization mechanism may be expected to 
be different than for the micelle- forming surfactants in Table 4.3.  In the case of 
vesicles, the aggregation number of surfactant is much larger than for micelles.  
Thus, the local concentration of surfactant in a single vesicle that can coat a 
growing drug particle is higher than for a single micelle.  The preferred curvature 
of the surfactant is more favorable for vesicles than micelles.  For vesicles, the 
interface with water is less curved than for the much smaller micelles and will 
more closely match that of the drug particles.  The better match in curvature may 
be expected to favor particle stability.  The growing drug nuclei may collide with 
a bilayer of the vesicle and dissolve.  The presence of the non-ionic surfactant 
Tween can aid the transport through the bilayer.  Since vesicles tend to be 
relatively stable, growth of drug particles by collision/coagulation is minimized.  
Thus, the particle may be expected to grow mostly due to a condensation 
mechanism25 within the bilayer as additional drug nuclei enter.  When the drug 
particle size becomes large enough, it can disrupt the vesicle structure and 
essentially cause an “unzipping” of the bilayer as the vesicle breaks.  The 
rearrangement of the surfactant may be expected, leaving a monolayer of the 
phospholipid on the particle surface with the polar heads solvated by water.  
SUVs may then become loosely associated with the hydrophilic groups on the 
outside surface of this monolayer.  Previous work has demonstrated the ability of 
phospholipid surfactants to adsorb on a hydrophobic surface as a monolayer.1   
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Unfortunately, in all the cases where Phospholipon 100H was used, the 
solutions foamed extensively and quickly became very viscous, or in the case of 
solution “C” even gelled, during the spray.  Changing the temperature of these 
solutions from 25 °C to 75 °C had no observable or measurable effect on the 
particles collected or the nature of the solution during RESAS.  When the solution 
becomes too thick, any further spraying yields large particles, as the surfactant 
can no longer diffuse to the particle surfaces as they precipitate and grow.  In the 
case of phospholipid solution “B,” particles were stabilized with mean diameters 
from 370-660 nm with broad distributions from 30 nm to 7 mm.  Phospholipid 
solution “C” quickly gelled during the spray, yielding the largest particles of any 
of the phospholipid combinations with approximate mean particle sizes of 2-4 mm 
and broad size distributions.  Phospholipid solution “D” stabilized particles 
moderately well, with mean sizes of 290-460 nm and particles ranging from 70 
nm to 3 mm.  Solutions “B, C, and D” also each had low trapping yields as the 
solutions became too viscous.  Likely, the difference between the performance of 
Lipoid E80 and Phospholipon 100H lies in the source (egg vs. soybean), and 
resulting differences in impurities.  Since phospholipid solution “A” produced the 
smallest particles, it will be the focus of the experiments in later sections 
concerning the effects of temperature, drug concentration, etc. 
In Figure 4.4, we show the x-ray diffraction patterns for cyclosporine 
before RESAS (lower curve), and for cyclosporine stabilized by Pluronic F127 
(upper curve).  Prior to processing, the cyclosporine is crystalline, showing 
multiple sharp peaks.  After processing by RESAS and stabilization by F127, the 
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cyclosporine crystal peaks have disappeared, suggesting the drug is now trapped 
in an amorphous state.  The two large peaks seen are due to the surfactant, 
Pluronic F127.  Since the entire sample produced with F127 was dried and 
analyzed (including the large particles), and the entire sample was amorphous, it 
is not unreasonable that the smaller drug particles trapped with the other 
surfactant systems could also be amorphous. 
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Figure 4.4     X-ray diffraction patterns for bulk cyclosporine (bottom) and 
cyclosporine processed by RESAS and stabilized by poloxamer 
F127 (drug/surfactant ratio= 0.2). 
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4.3.3 Effect of suspension concentration  
Tables 6,7,8 illustrate the effect of the drug concentration, which is a 
function of spray time, on the particle size for bath temperatures of 25, 45, and 80 
°C, respectively.  In all of the experiments, the stabilizing solution was 
phospholipid formulation “A” at the higher concentration levels as shown in 
Table 4.4.  The starting vesicle size in the solution, as listed in Table 4.4, was 10-
50 nm and they are likely SUVs.  Upon examination with TEM, the vesicles 
appeared similar to those shown in Figure 4.3a.  The tables show the actual 
stabilizing solution temperature measured within the separatory funnel in addition 
to the same entries found in Table 4.5. 
Table 4.6 shows the particle size for a bath temperature of 25.0 °C.  At a 
drug concentration of ~20 mg/mL, particles collected had a mean diameter of 
500-650 nm with sizes ranging from 70 nm – 2 mm.  At ~40 mg/mL the mean 
particle size increased to 730 nm with very broad distributions.  The average 
particle size grew by as much as 50% when doubling the drug concentration.  A 
further increase in drug concentration to 46 mg/mL produced a substantial 
increase in particles larger than 1 micron indicating loss of stabilization against 
aggregation. 
In Table 4.7 versus Table 4.6 the only difference in experimental 
conditions was the stabilizing solution bath temperature, which was 45.0 °C.  
Initially, at a drug:surfactant ratio of ~0.1 (roughly 2 times the equilibrium 
solubility) the particle mean diameters were only 160-180 nm with narrow size 
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Table 4.6.  Effect of suspension concentration on cyclosporine microparticles 
prepared by RESAS for a stabilizing solution bath temperature of 25 °C.a 
Stabilizing 
sol’n temp. 
°C 
Drug 
conc. 
(mg/mL) 
Yield 
% (w/w) 
Particle 
mean 
(nm) 
Particle size 
distribution 
(nm) 
Drug/surf. 
ratio 
(g/g) 
14 18.4 89 650 70-140 (28%),  
240-450 (36%), 
1000-1900(36%) 
0.15 
13.3 19.4 96 500 90-190 (45%), 
530-1260 (55%) 
0.16 
14.8 24.2 110 630 120-210 (47%), 
760-1440 (53%) 
0.20 
15.8 39.0 110 730 50-80 (4%),  
160-290 (33%), 
750-1500 (63%) 
0.33 
13.7 39.8 80 960 80-160 (14%),  
480-910 (74%), 
2700-5200 (12%) 
0.33 
13.6 45.9 94 1700 80-160 (12%),  
500-1150 (74%), 
5000-10000 (14%) 
0.38 
a  Tsoln = 30.0 °C, Tpreheater = 60.0 °C, DP = 345 bar, Tbath = 25.0 °C, solution flowrate = 2.5 
mL/min 
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Table 4.7.  Effect of suspension concentration on cyclosporine microparticles 
prepared by RESAS for a stabilizing solution bath temperature of 45 
°C.a  
Stabilizing 
sol’n temp. 
°C 
Drug 
conc. 
(mg/mL) 
Yield 
% (w/w) 
Particle 
mean 
(nm) 
Particle size 
distribution 
(nm) 
Drug/surf. 
ratio 
(g/g) 
32 10.3 70 160 80-110 (67%), 
260-350 (33%) 
0.09 
33 13.0 87 180 80-110 (47%), 
220-290 (53%) 
0.11 
31.2 15.8 89 280 40-70 (6%), 
140-220 (67%), 
450-760 (27%) 
0.13 
29.8 17.5 95 290 110-160 (44%), 
370-470 (56%) 
0.15 
31.1 17.6 93 260 90-120 (33%), 
290-400 (67%) 
0.15 
30.3 26.2 72 380 40-80 (10 %), 
200-370 (71%), 
690-1100 (19%) 
0.22 
31.2 24.4 74 310 40-100 (13%), 
200-520 (87%) 
0.20 
30.5 31.7 83 390 30-50 (2%), 
140-230 (44%), 
430-820 (54%) 
0.26 
a  Tsoln = 30.0 °C, Tpreheater = 60.0 °C, DP = 345 bar, Tbath = 45.0 °C, solution flowrate = 2.5 
mL/min 
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Table 4.8.  Effect of suspension concentration on cyclosporine microparticles 
prepared by RESAS for a stabilizing solution bath temperature of 80 
°C.a  
 
Stabilizing 
sol’n temp. 
°C 
Drug 
conc. 
(mg/mL) 
Yield 
 
% (w/w) 
Particle 
mean 
(nm) 
Particle size 
distribution 
(nm) 
Drug/surf. 
ratio 
(g/g) 
      
56.8 12.6 88 220 60-90 (45%), 
270-380 (55%) 
0.11 
54.3 14.8 88 230 60-90 (40 %), 
290-390 (60%) 
0.12 
57.2 17.6 72 320 60-100 (28%), 
310-600 (72%) 
0.15 
53.7 23.8 62 390 80-120 (34%), 
440-650 (66%) 
0.20 
53.8 27.0 72 460 100-140 (31%), 
500-750 (69%) 
0.23 
52.7 39.8 99 480 50-100 (48%), 
170-360 (18%), 
860-1770 (34%) 
0.33 
50.3 54.0 139 500 40-60 (26%), 
100-200 (11%), 
500-920 (63%) 
0.45 
      
 
a  Tsoln = 30.0 °C, Tpreheater = 60.0 °C, DP = 345 bar, Tbath = 80.0 °C, solution flowrate = 2.5 mL/min 
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distributions.  At a drug surfactant ratio of ~0.15, the particle mean increased to 
260-290 nm, and at 0.25, it reached 310-390 nm with a slightly broader size 
distribution.  In all cases the particles were much smaller than those produced 
with Tween 80. 
In Table 4.8, the stabilizing solution bath temperature was 80 °C.  For a 
given drug loading, each of the properties of the particles was similar to that for a 
bath temperature of 45 oC.  In all three cases, the particle size increased 
substantially with drug concentration, which increases with spray time.  Figure 
4.5 demonstrates the trends in particle growth more clearly.  For the two higher 
stabilizing solution temperatures, the particle size increases approximately 
linearly with drug concentration, with only a small increase in size with 
temperature.  For a temperature of 14 °C, the size is larger by a factor of about 
two and the scatter about the linear correlation with drug concentration is much 
larger. 
Several factors may be expected to cause the increase in particle size with 
drug concentration.  The first factor is surfactant depletion in the aqueous solution 
as the SUVs coat the particles and form drug-surfactant aggregates.  As the spray 
time and drug concentration increase, fewer of the initial SUVs are available for 
stabilizing incoming particles.  Another factor is that the particle collision rate 
increases approximately with the square of the particle concentration.  In addition, 
an increase in the drug concentration raises the drug/surfactant ratio in the 
aqueous solution.  The resulting increase in total drug surface area and decrease in 
surfactant coverage of this drug surface area may lead to greater aggregation of 
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Figure 4.5   Effect of drug concentration and stabilizing solution temperature on 
cyclosporine particles produced by RESAS with phospholipid 
solution “A” as the stabilizer.  Tsoln = 30.0 °C, Tpreheater = 60.0 °C, DP 
= 345 bar, Tbath = 25, 45, 80.0 °C, solution flowrate = 2.5 mL/min 
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the surfactant coated drug particles.  Another factor is simply the greater time for 
particle growth due to shear- induced aggregation caused by the flowing carbon 
dioxide.  Once removed from the process, however, the drug suspensions were 
extremely stable with little change in particle size measurable by DLS even after 
weeks of storage, as discussed in greater detail below.  
4.3.4 Effect of stabilizing solution temperature 
The ability for the phospholipid-based surfactants to stabilize the particles 
may be expected to depend upon the temperature of the medium within the 
receiving vessel.  Most phospholipid vesicles exhibit a transition temperature 
from a rigid gel- like state to a fluid liquid-crystalline state.  As temperature 
increases, the phospholipid chains within the vesicles go from a very rigid, 
ordered state, to one that is more flexible and can allow diffusion across the 
bilayer.  The rigidity of the phospholipid tails, and hence the vesicles, could affect 
the surfactant’s ability to rearrange in order to stabilize the drug particles as they 
precipitate.  The effect of lipid chain melting behavior, and hence the lipid’s 
ability to orient at the surface of emulsion droplets has been studied.28  Dry Lipoid 
E80 powder was analyzed by DSC to determine the chain melting point, as shown 
in Figure 4.6.  The melting transition appears slightly above room temperature, at 
24-29 °C.  While the location of the transition agrees with previous studies,28 the 
transition enthalpy is lower here.  This difference is likely due to adsorbed water.  
When 10 % (w/w) of lipoid E80 was added to water, however, the DSC 
thermogram was dominated by the water melting peak, and since the transition 
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enthalpy was already low, it could no longer be detected.  This effect was seen 
previously.28   Also, the fact that it is hard to detect a clear transition in solution is 
not unexpected for lipid samples that are not made of pure components or that 
have additives such as cholesterol.36   While the presence of Tween 80, mannitol, 
and even the drug in the vesicles would be expected to further broaden/shift the 
transition point,28,36-41 this effect could unfortunately not be demonstrated with 
this system.   
Note that in each of the tables, the actual stabilizing solution temperature 
near the nozzle is significantly lower than that of the water bath used to heat the 
medium.  This cooling is due to the expanding CO2 gas.  As seen in Fig. 3, the 
particle sizes measured when the stabilizing solution temperature was above 30 
°C were nearly the same at similar drug loadings, regardless of the stabilizing 
solution bath temperature.  However, a la rge increase in particle size was noted 
for the cases where the stabilizing solution was only 14 °C.  It’s likely that at this 
temperature the phospholipid chains are too rigid to rearrange and stabilize the 
growing particles as rapidly as at the higher temperatures.  The increase in the 
viscosity of water at locally low temperatures could further inhibit diffusion and 
rearrangement of surfactant.  There could also be an effect of locally colder 
temperatures in the vicinity of the nozzle tip decreasing supersaturation based on 
the phase diagram26, slowing particle nucleation and producing larger particles.  
This supersaturation effect is discussed in greater detail in the next section on the 
effect of preheater temperature for a constant stabilizing solution temperature. 
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Figure 4.6       DSC thermogram of bulk Lipoid E80. 
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4.3.5 Effect of preheater temperature 
Cyclosporine becomes less soluble in CO2 as temperature increases.26 
Therefore it is expected that at higher preheater temperatures, the depressurization 
in the nozzle will cause the solution to pass through the phase boundary more 
quickly than at lower temperatures, leading to higher levels of 
supersaturation.15,25,26,42   The greater supersaturation, in turn, leads to higher rates 
of nucleation, which would lead to the formation of smaller particles, if 
aggregation may be controlled. 
Table 4.9 illustrates the effects of the preheater temperature on the 
cyclosporine particle size.  The first two entries show the results through a nozzle 
at a flow rate of 0.88 mL/min at a DP of 345 bar.  At a low preheater temperature 
of 30 °C, the particles produced at this flowrate were larger than 10 mm and 
quickly settled out, leaving only drug solubilized in the SUVs.  With a bath 
temperature of only 30 °C, the stabilizing solution temperature became too cold 
for adequate stabilization as discussed above.  At a higher preheater temperature 
of 60 °C, and at a drug:surfactant ratio of 0.24 the particles had a mean size of 
530 nm.  The higher preheater temperature resulted in less local cooling for this 
nozzle flowrate, and allowed the stabilization of particles. 
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Table 4.9.  Effect of preheater temperature on cyclosporine microparticles 
prepared by RESAS of a 1.0 % (w/w) solution into 10.0 mL of 
phospholipid mixture A.a  
 
Tpre 
°C 
Stabilizing 
sol’n temp. 
°C 
Drug 
conc. 
(mg/mL) 
Yield 
 
% (w/w) 
Particle 
mean 
(nm) 
Particle size 
distribution 
(nm) 
Drug/surf. 
ratio 
(g/g) 
       
30b 22.0 2.5 30  30-130, 
>10 mm 
0.02 
60b 21.2 24.0 80 530 190-290 (82%), 
1500-2500 (18%) 
0.24 
       
30 32.1 27.8 100 400 50-240 (40%), 
440-720 (60%) 
0.23 
30 31.7 19.3 82 380 90-170 (15%), 
270-590 (85%) 
0.16 
       
60 32.2 14.3 98 280 40-180 (68%), 
420-770 (32%) 
0.12 
60 31.8 11.9 84 320 110-150 (41%), 
400-540 (59%) 
0.10 
       
80 31.6 11.7 79 110 70-100 (90%), 
280-380 (10%) 
0.10 
80 32.0 13.1 78 190 20-140 (70%), 
280-380 (30%) 
0.11 
 
a Tsoln = 30.0 °C, Tbath = 45.0 °C, DP = 345 bar, solution flowrate = 2.5 mL/min 
b Tsoln = 30.0 °C, Tbath = 40.0 °C, DP = 345 bar, solution flowrate = 0.88 mL/min 
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In the remainder of the results in Table 4.9, the solution flowrate was 2.5 
mL/min at the same DP of 345 bar.  As the preheater temperature was changed 
from 30 to 80 °C, the mean particle size decreased.  The drug/surfactant ratio was 
fairly constant, especially for the higher two preheater temperatures.  Notice that 
the preheater temperature had essentially no effect on the stabilizing solution 
temperature due to the efficient heat transfer in the nozzle and the jet, and the 
large change in latent heat for compressed CO2 relative to the sensible heat.  
Consequently, the rigidity of the phospholipids in the aqueous solutions was 
essentially constant.  Thus, the decrease in particle size is most likely due to the 
faster nucleation rate produced by the higher supersaturation at the higher 
preheater temperatures.    
 
4.3.6 Effect of nozzle size  
Table 4.9 also illustrates the effect of nozzle size on the particle size.  Two 
crimped nozzles were compared with similar operating pressures, DP = 345 bar, 
but with flow rates of 0.88 mL/min and 2.5 mL/min.  The greater restriction for 
the slower flowrate nozzle indicates that the crimping and filing process produced 
a smaller elliptical orifice.  The smaller, low flowrate, nozzle appears to produce 
larger particles than the high flowrate nozzle.  While smaller droplet sizes would 
be expected with the smaller nozzle due to more intense atomization, the 
dominating factor on particle stability in this system appears to be the conditions 
of the stabilizing solution.  At the lower flowrate, the jet is less forceful and 
creates less mixing/turbulence within the stabilizing solution.  The weaker mixing 
 119 
is evident in the lower local temperature within the stabilizing solution.  At the 
higher flowrates, the solution is agitated more intensely, and heat is transferred 
throughout the fluid within the separatory funnel more efficiently, producing a 
higher local temperature.  Since the lower flowrate nozzle creates less turbulence, 
the particles and surfactant are not mixed as well leading to less effective 
stabilization.  Also, the particles are not carried away from the jet as quickly, 
allowing for potentially more collisions prior to complete stabilization.  In the 
future, this limitation could be overcome by stirring the solution.   
The use of a much larger 50 mm i.d. x 10 cm long straight capillary nozzle 
in RESAS led to low yields (<35%) and the formation of >10 mm particles.  Also, 
this nozzle tended to plug easily as compared to the crimped nozzle design, which 
never plugged during a spray.  In the case of the capillary nozzle, the 
depressurization profile occurs over the entire length of the nozzle, resulting to 
some particle nucleation and growth within the nozzle where it cannot be 
stabilized. 
 
4.3.7 Long term stability 
For all of the samples produced, initial particle size measurements were 
made within 24 hours of the RESAS spray.  Also, the stability of the particle size 
after 1 month of storage at 4 oC and under nitrogen was examined and the data is 
shown in Table 4.10.  Each sample was gently inverted 5-10 times and then 
allowed to sit for 1 hour prior to analysis.  For each of the non-phospholipid 
surfactants, the particles settled completely and caked at the bottom of the vial.  
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These samples were not redispersible, even by sonication.  The samples produced 
by RESAS with phospholipid solution “A” had good stability, with no settling 
observed for most of the suspensions without shaking.  Even in cases where there 
was some settling present, the samples were easily redispersed by the gentle 
inversions.  Most of the samples experienced some growth, or small broadening in 
the size distribution.  In one case, the particle size grew considerably during the 
one month period, likely due to the very high drug:surfactant ratio (>0.5) in this 
system due to the low amount of surfactant and also showed instability in the 
form of settling.  In the case where the particle size appears to decrease, it’s likely 
that some of the larger particles have settled out (not visible to eye) and were 
simply not captured in the sample analyzed by DLS. 
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Table 4.10.   Suspension stability after 1 month of storage at 4°C for phospho lipid 
mixture A - 10/2/5.5 % (w/w) Lipoid E80/Tween 80/mannitol. 
 
Original 
mean 
nm 
Mean 
after 1 mo. 
nm 
Distribution 
after 1 mo. 
nm 
% change 
    
260 320 30-50(25%),  
120-190(16%), 
410-710(59%) 
20 
220 750a 50-230(17%),  
660-1200(83%) 
240 
1700 720 100-160(10%), 
650-1000(90%) 
-40 
390 700 80-140(29%),  
200-300(6%),  
820-1230(65%) 
80 
460 560 50-240(47%),  
560-1780(53%) 
20 
400 740 60-90(41%),  
170-350(16%), 
1200-2000(43%) 
85 
320 420 50-150(46%),  
220-410(15%), 
680-1120(39%) 
30 
    
a settling height was 7% of the total; 1.0/0.2/0.55 % (w/w) Lipoid E80/Tween 80/mannitol 
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4.4 CONCLUSIONS  
Phospholipid vesicles mixed with nonionic surfactants stabilize 
cyclosporine particles produced by RESAS with mean diameters as small as 200-
300 nm.  This size range is several hundred nanometers smaller than produced by 
RESAS for particles stabilized by Tween 80.  Many of the size distributions are 
bimodal, according to DLS measurements and TEM, consisting of vesicles with 
very low drug concentrations and drug particle aggregates stabilized with 
vesicles.  As the local temperature of the aqueous stabilizing solution is increased 
above 25 o C, the vesicles become less rigid and stabilize the drug particles more 
effectively leading to smaller particles.  For a given stabilizing solution 
temperature, the particle size also decreases with an increase in preheater 
temperature due to greater supersaturation in the nozzle and more rapid 
nucleation.  High drug loadings in the aqueous suspensions, as high as 54 mg/mL, 
could be achieved with particle sizes of ~500 nm. This concentration is ~10 times 
the equilibrium solubility in the aqueous surfactant solution.  From X-ray 
diffraction data of dry powder samples it was observed that the particles are 
stabilized rapidly enough to trap the  drug in an amorphous state.  Long-term 
stability studies of the suspensions stored at 4 °C indicate only modest particle 
growth, over 1 month.   
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CHAPTER 5 
Conclusions and Recommendations 
5.1 CONCLUSIONS  
1. The Vapor-over-Liquid PCA (V/L PCA) process was successfully used to
encapsulate a protein into PGLA.  The PGLA particles had to be large enough
to encapsulate the protein and should not agglomerate.  In contrast, the
primary particles (0.5 to 5 mm) were too small for encapsulation when the
solution was sprayed directly into liquid or supercritical CO2; furthermore, the
particles were highly agglomerated.  By delaying precipitation in a vapor CO2
phase over a liquid CO2 phase, much larger primary particles were formed,
from 5 to 70 mm.
2. The amorphous polymer PGLA is highly plasticized by CO2.  Dissolution of
CO2 into PGLA depresses the Tg from the normal value of 45 °C to
approximately -40 °C at 276 bar, based upon observation of particle
agglomeration.  Below -40°C, the polymer remains as a non-sticky free-
flowing powder in the presence of CO2 at 276 bar.  Below -30°C, the rate of
mixing between CH2Cl2 and liquid CO2 decreases appreciably.  At an optimal
temperature of -20 °C, the highly viscous PGLA microspheres do not
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agglomerate, yet the temperature is high enough to achieve adequate mixing 
between liquid CO2 and the organic solution.  An additional benefit of 
operating at colder temperatures is the relatively low pressure.  At -20°C, the 
saturation pressure of CO2 is 19.7 bar, compared to 61.4 bar at 23 °C.  
Experimental temperatures of 0 °C or above, or below -30°C yielded only 
large (>1000 µm) agglomerates.  At high temperatures the particles are too 
sticky due to dissolved CO2, and at low temperatures, the organic solution and 
CO2 mix too slowly. 
 
3. The vapor-over-liquid PCA process forms microspheres in the 5-70 µm range 
when a 5.0 % solution of PGLA in dichloromethane is sprayed at 0.22 
mL/min through a 100 µm diameter nozzle into static CO2 at -20 °C.  Lower 
concentrations yielded smaller primary particles whereas, highly viscous, 
concentrated solutions above 10.0 wt. % led to skin formation in the vapor 
phase and subsequent agglomeration in the liquid CO2 phase.  The thin skin is 
weak due to low molecular weight and dissolved CO2, and hence rupturing 
occurs upon impact at the liquid interface, leading to agglomeration.  Particle 
sizes did not change appreciably with solution flow rate in the "dripping" 
regime.  At the onset of streaming flow, there was a higher percentage of large 
particles, while the particle size range remained the same.  The most spherical 
and uniform particles ranging in size from 3-25 µm in diameter were 
produced by flowing CO2 at high velocity through an annular region in a 
coaxial nozzle to provide mixing at the interface.   
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4. Encapsulation of 1-10 µm lysozyme particles proved successful for the 5-70
µm PGLA microspheres for a 1:10 ratio by weight of protein to polymer and a
5 wt % polymer solution.  The presence of lysozyme in the particles was
demonstrated by SEM analysis, optical microscopy, and EDS.  A high
encapsulation efficiency for this process is favored by the fact that the protein
and polymer precipitate together in small droplets.  The use of protein
suspensions extends the applicability of the PCA process substantially, since
many proteins are insoluble in organic solvents and are less likely to be
denatured when suspended.
5. Rapid Expansion from Supercitical to Aqueous Solution (RESAS)
incorporates an aqueous stabilizing solution to trap submicron particles of a
water-insoluble pharmaceutical compound.  In RESAS, the surfactant diffuses
rapidly to the particle surface to impede particle agglomeration and growth.
Cyclosporine microparticles ~ 0.5 mm in diameter were formed by spraying a
1.0 % (w/w) solution (in CO2) into 1.0 and 5.0 % (w/w) Tween-80 solutions
to prevent microparticle flocculation and agglomeration.  RESAS may be
expected to be a general process to produce smaller particle sizes of organic
and inorganic water- insoluble materials than in the case of RESS into air.
6. By RESAS, cyclosporine particles 500-700 nm in diameter were stabilized for
drug concentrations as high as 6.20 mg/mL and 37.5 mg/mL in 1.0 and 5.0 %
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(w/w) Tween-80 solutions, respective ly.  At a drug:surfactant ratio above 0.6-
0.7 the surfactant can no longer stabilize the particles, resulting in broader size 
distributions.   
 
7. Phospholipid vesicles mixed with nonionic surfactants stabilize cyclosporine 
particles produced by RESAS with mean diameters as small as 200-300 nm.  
Many of the size distributions are bimodal, according to DLS measurements 
and TEM, consisting of vesicles with very low drug concentrations and drug 
particle aggregates stabilized with vesicles.  As the local temperature of the 
aqueous stabilizing solution is increased above 25 o C, the vesicles become 
less rigid and stabilize the drug particles more effectively leading to smaller 
particles.  For a given stabilizing solution temperature, the particle size also 
decreases with an increase in preheater temperature due to greater 
supersaturation in the nozzle and more rapid nucleation.   
 
8. Using phospholipid stabilizers, high drug loadings in the aqueous suspensions 
(as high as 54 mg/mL) could be achieved with particle sizes of ~500 nm. This 
concentration is ~10 times the equilibrium solubility in the aqueous surfactant 
solution.  From X-ray diffraction data of dry powder samples it was observed 
that the particles are stabilized rapidly enough to trap the drug in an 
amorphous state.  Long-term stability studies of the suspensions stored at 4 °C 
indicate only modest particle growth, over 1 month.   
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5.2 RECOMMENDATIONS 
1. It is recommended that alternative supercritical fluids should be examined for 
use in the RESAS process.  Since drugs may have limited solubility in SC 
CO2, others such as pentane or diethyl ether could be tried.  Also, the 
supercritical solvents could be blended.  Also, the possibility of adding 
cosolvents, such as methanol or acetone, exists.   
 
2. It is recommended that addition of surfactant to the supercritical fluid phase in 
RESAS be examined.  This could enhance solubility in the CO2 phase if the 
surfactants chosen form micelles in CO2.  Also, this may allow even faster 
stabilization of the particles formed since the surfactant and drug are more 
likely to be in intimate contact during precipitation.  Depending on the 
solubility of surfactant in CO2, perhaps the total surfactant necessary for 
particle stabilization could be split between the CO2 and aqueous phases. 
 
3. It is recommended that other means of testing the particle-surfactant structure 
in water be evaluated.  A possibility includes freeze-fracture SEM, where the 
solution is frozen and cut providing cross-sectional views of the suspension.   
 
4. It is recommended that other stabilizing surfactants for RESAS be examined.  
The phenomenon of critical surface area coverage for suspension stability vs. 
surfactant type and size could be examined more thoroughly. 
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5. It is recommended that further testing be conducted on drug-active
suspensions be performed such as dissolution rates.  The rate vs. stabilizer
type could be examined.  Also, the rate vs. particle size could be examined.
6. It is recommended that method should be developed for the capture of larger
quantities of powder from PCA.  Powders formed could then be tested for
multiple purposes.  Encapsulated products could be dissolution rate tested.
Drug powders could be tested for crystallinity.  Polymer blends could be
tested for film-forming and other mechanical properties.
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